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ABSTRACT 
 
The research objectives were to describe the age and gender of adult HIV positive 
clients on ART who received IPT; the incidence of tuberculosis among clients that 
received IPT and the defaulter rate among those that were commenced on IPT. 
Quantitative non-experimental descriptive retrospective cohort study was undertaken to 
ascertain the incidence of tuberculosis among adult HIV positive clients who received 
IPT. 104 clinic records of HIV positive adult clients accessing care at Isithebe Clinic, 
iLembe-South Africa who were commenced on IPT between 01 July 2010 and 30 
November 2011 were analysed. The study found that 66 of 104 (63.5%) study 
respondents completed the course of IPT and the majority of those that defaulted were 
due to poor quality of care. Gender was statistically found to have played a role on 
whether a patient completes IPT. None of the study respondents that completed IPT 
was diagnosed with TB disease.  
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CHAPTER 1 
 
Orientation to the study  
 
 
1.1 INTRODUCTION 
 
With an estimated 5.6 million people living with HIV in 2011, South Africa’s epidemic 
remains the largest in the world (National Department of Health [NDOH] 2012).  South 
Africa is also the country with the third highest tuberculosis (TB) burden globally, only 
lagging behind China and India, which have significantly larger populations (NDOH, 
2011:4). The World Health Organization (WHO) (2012:151) reported that an estimated 
500 000 people living in South Africa, including ones who were HIV positive, contracted 
TB in 2011. 
 
Infection with human immunodeficiency virus (HIV) has been identified as the strongest 
risk factor in the reactivation of latent or new Mycobacterium tuberculosis infection to 
active TB disease. TB is also the commonest cause of morbidity and mortality among 
the HIV-infected population in South Africa and studies have shown that TB accelerates 
HIV disease progression (NDOH 2010b:2). 
 
Isoniazid preventive therapy (IPT) is one of the interventions recommended by the 
WHO and the South African NDOH for the prevention of progression to active TB 
disease in people living with HIV (PLHIV). However, no known scientific study has been 
undertaken in iLembe district regarding the incidence of TB among HIV-positive clients 
who received IPT.  
 
1.2 BACKGROUND TO THE RESEARCH PROBLEM 
 
Since the first report of HIV/AIDS was made by two physicians in the United States of 
America (USA), the number of people living with the disease has steadily increased and 
the epidemic moved into a generalised state impacting on many segments of society. 
An estimated 34 million people were living with HIV at the end of 2011 (UNAIDS, 
2012:4). The Joint United Nations Programme on HIV and AIDS (UNAIDS) further 
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indicates that sub-Saharan Africa still bears an inordinate share of the global HIV 
burden. An estimated 69% of people living with HIV (PLHIV) globally reside in sub-
Saharan Africa. With an estimated 5.6 million people living with HIV in 2011, South 
Africa’s epidemic remains the largest in the world (NDOH 2012). KwaZulu-Natal 
province has consistently recorded the highest provincial HIV prevalence since 1990 
(NDOH 2010a:43).  
 
The population of iLembe District where the study was conducted grew from 568 498 in 
2006 (Enterprise ILembe [s.a.]:13) to 606 809 in the latest census report (SSA 
2012:117). Only about 28% of the population were formally and informally employed at 
the end of the second quarter in 2011. In this district, the not-economically active 
persons account for 64.2% of the district population (Enterprise iLembe [s.a.]:17). The 
reported high unemployment and resulting poverty noted in the district has been shown 
to be associated with increased exposure to HIV and other sexually transmitted 
infections (STIs) (Buvé, Bishikwabo-Nsarhaza & Mutangadura 2002:2014). HIV 
prevalence among antenatal women was 35.4% in 2011 (NDOH 2012:17) while the HIV 
prevalence for the entire iLembe population was 16.6% as in the first quarter of 2011 
according to Enterprise iLembe. 
 
TB has existed in the world for centuries. The incidence of TB was generally on the 
decline in the world until the early 1980s (FPD 2010a:151). The Foundation for 
Professional Development (FPD) indicates that from the mid 1980’s, an increase of 
cases was reported in the USA, parts of South East Asia, and East, Central, West and 
Southern Africa. While various factors contributed to the upsurge in the world TB 
burden, the groups with the greatest increase in TB were also the groups with the 
highest HIV rates (FPD 2010a:151). 
 
From a recorded 7-8 million cases in 1993 when the WHO declared TB a global public 
health emergency, the spread of TB increased  to about 9 million new cases in 2011 
(WHO 2011b:3; 2012:3). TB is the second leading cause of death from an infectious 
disease worldwide after HIV, accounting for an estimated 1.4 million deaths in 2011. 
This included an estimated 430 000 deaths from TB among PLHIV (WHO 2012:3).  
 
South Africa is the world’s third largest TB burdened country in the world, lagging 
behind China and India, which have significantly larger populations (NDOH 2011a:4). 
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South Africa has the fifth-largest DR-TB burden in the world due largely to the high 
prevalence of HIV in the country and inadequate management of TB (NDOH 2011b:4). 
An estimated 500 000 people in South Africa contracted TB in 2011 with 66% of them 
occurring in PLHIV (WHO 2012:151). The WHO further indicates that about 25 000 of 
the deaths that occurred in the country in 2011 were due to TB disease which has an 
incidence rate of 993 per 100 000 people. 
 
ILembe District in KwaZulu-Natal where the study was carried out also has a high TB 
burden. According to a report emanating from the KwaZulu-Natal Tuberculosis 
Programme, a total of 3643 PLHIV were diagnosed with TB disease in the district in 
2012 (KZN Tuberculosis Programme 2012). This figure represents 62.1% of the 
absolute number of clients diagnosed with TB disease in the district. However, 13% of 
them are yet to test for HIV. 
 
HIV is the strongest risk factor yet recognised in the reactivation of latent or new 
Mycobacterium tuberculosis infection to active TB disease (WHO, 2011a:1). The 
increased risk of active TB occurs soon after HIV sero conversion and doubles by the 
end of the first year of HIV infection (Granich, Akolo, Gunneberg, Getahun, Williams & 
Williams 2010:S215). In 2011, about 1.1million PLHIV were newly diagnosed with TB, 
representing 12.4% of the global total number of PLHIV (UNAIDS 2012:54). 
 
The WHO (2011a:1) has provided clear recommendations about interventions needed 
to prevent, diagnose and treat TB in PLHIV. The recommendations are collectively 
referred to as “collaborative TB/HIV activities”. They include HIV testing of TB patients, 
provision of ART and Cotrimoxazole Preventive Therapy (CPT) to TB patients living with 
HIV, HIV-preventive services for TB patients, intensified TB case-finding among people 
living with HIV, Isoniazid preventive therapy (IPT) for PLHIV who do not have active TB 
and infection control in healthcare and assembly settings. Active TB screening offers 
the opportunity to provide preventive therapy for those who do not have symptoms and 
signs of TB. 
 
IPT refers to the intake of isoniazid by individuals with latent infection with 
Mycobacterium tuberculosis in order to prevent the progression to active TB disease 
amongst People Living with HIV (NDOH 2010b:2).  Adults and adolescents living with 
HIV who have an unknown or positive tuberculin skin test (TST) status and who are 
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unlikely to have active TB should receive at least six months of IPT as part of a 
comprehensive package of HIV care (WHO 2011a:6). The WHO strongly recommends 
with high quality of evidence that IPT should be given to such individuals irrespective of 
the degree of immunosuppression, and also to those on ART, those who have 
previously been treated for TB and pregnant women. In practice however, TST which 
identifies people with latent TB infection often constitutes an impediment for the 
provision of IPT. It is no longer required compulsorily to identify people eligible for IPT in 
the South African public health setting (NDOH 2010b:4). IPT is thus one of the 
interventions recommended by the WHO that reduce the morbidity and mortality from 
TB in PLHIV (WHO 2011b:1). The protective effect of TB preventive therapy is expected 
to last for approximately 18 months and therefore, the therapy should be given once 
only within this period (NDOH 2010b:5). 
 
The theoretical foundation of the study is based on the submission by WHO (2011:71) 
that high quality of evidence exists to the fact that provision of IPT reduces incidence of 
active TB disease in individuals affected by HIV/AIDS. The study was thus carried out to 
ascertain the veracity of this theory in a rural setting located in iLembe district, South 
Africa.  
 
1.3 RESEARCH PROBLEM 
 
There is a need for scientific evidence regarding the incidence of TB among HIV-
positive clients who received IPT in Isithebe Primary Healthcare Centre (PHC) within 
the 18-month period that the protective effect of IPT is expected to last. Accordingly, the 
researcher undertook this evidence-based study to explore and reveal the impact of 
isoniazid as a preventive therapy meant to protect HIV-positive patients. 
 
1.4 AIM 
 
The aim of the study was to describe the incidence of TB amongst HIV-positive clients 
who received IPT in Isithebe PHC. 
 
1.5 RESEARCH OBJECTIVES 
 
The research objectives were to describe the 
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 demographic characteristics (age and gender) of adult HIV-positive clients on 
antiretroviral therapy who received isoniazid preventive therapy 
 incidence of TB among clients who completed a 6-month course of isoniazid 
preventive therapy 
 defaulter rate for adult clients who commenced isoniazid preventive therapy 
 
1.6 RESEARCH DESIGN AND METHODOLOGY 
 
1.6.1 Research design 
 
A research design refers to the overall structure or plan for the research (Bowling 
2009:158). The researcher chose a quantitative non-experimental descriptive 
retrospective cohort study to ascertain the incidence of TB among adult HIV-positive 
clients who received a six-month course of IPT at the clinic between July 2010 and 
November 2011. A non-experimental design was considered appropriate for the study 
because there was no manipulation of the independent variables, no intervention, and 
the setting was not controlled (Brink, Van der Walt & Van Rensburg 2012:112).  
 
A descriptive study refers to a simple description of the health status of a community 
based on routinely available data or on data obtained in special surveys (Bonita et al 
2006:40) therefore the study was descriptive. In studies with retrospective designs a 
phenomenon existing in the present is linked to phenomena that occurred in the past 
(Polit & Beck 2012:224). The study was retrospective as data for the study was 
collected from records of HIV-positive patients who accessed IPT from Isithebe Clinic 
between July 2010 and November 2011. The study thus aimed to explore whether TB in 
the study population was linked to their intake of IPT within the designated period. A 
cohort study was chosen because the records of a group of people who share certain 
characteristics, which in this case were HIV-positive clients commenced on IPT, were 
followed during and after treatment (Joubert & Ehrlich 2007:79). The variables were not 
manipulated (Grove, Burns & Gray 2013:215) (see chapter 3 for discussion).  
 
1.6.2 Research setting 
 
The study was carried out at Isithebe Clinic located in iLembe Health District, KwaZulu-
Natal Province, South Africa. 
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1.6.3 Population  
 
A research population refers to the whole collection of cases in which a researcher is 
interested while the accessible population is the cases that conform to the set study 
criteria and are available for the study (Polit & Beck 2012:273). 
 
The accessible population for the study were the 104 clinic records of HIV-positive 
patients accessing care at Isithebe Clinic who were aged over 18 and were started on 
IPT between 01 July 2010 and 30 November 2011. Chapter 3 discusses the population 
fully.  
 
The target population is the aggregate of cases that the study generalised and in this 
study were the entire HIV-positive adult clients that received IPT in iLembe district.  
 
1.6.4 Sampling 
 
All the patients’ records that met the inclusion criteria were used for the study. They 
were 104 HIV-positive patients that were enrolled on IPT within the period being studied 
according to the daily clinic register after data cleaning.  
 
To be included in the study, the patients had to be HIV-positive adults aged 18 and 
older, to have been screened for TB and commenced on IPT within the stated period.  
 
The records of patients who were stopped from continuing IPT due to adverse drug 
reactions; died before completing the therapy; transferred out of the clinic within the 
period under review, or were lost to follow-up were excluded. 
 
1.6.5 Research technique 
 
The researcher used a data-gathering sheet to compile information from the identified 
clinic records and registers. The data included the patient’s age at the commencement 
of IPT; gender; date of commencement of IPT; monthly collection of INH for IPT; 
indication of whether patient completed the full course of IPT; any other co-morbidity; 
any diagnosis of TB after the IPT, and an indication of when the diagnosis of TB 
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disease was made, where appropriate. The compilation of the data was done solely by 
the researcher (see chapter 3 for detailed discussion). 
 
1.6.6 Data collection  
 
The daily clinic attendance registers, IPT register and the folders of the patients were 
the patients’ records utilised for the study. The choice of review of records was to 
minimise cost and time, yield data that could not be influenced by the project and also 
allow for comparison. Where there was incomplete data, other clinic or laboratory 
records were used as much as possible (Katzenellenbogen & Joubert 2007:108). For 
the purpose of this study, incomplete information regarding the TB treatment was 
sourced from the TB register. The electronic ART patient records maintained at the 
facility were also used to access information regarding treatment of the patient missing 
from the aforementioned records. Strict confidentiality was maintained while collecting 
the data and the names of the patients were replaced with unique letters on the data 
capture sheet.  
 
1.6.7 Data analysis 
 
1.6.7.1 Data handling 
 
Before full analysis, issues concerning data collection process were reviewed. 
Information regarding the extent of missing data, data on the characteristics of 
respondents and data on the setting in which the information was collected were 
properly reviewed (Katzenellenbogen & Joubert 2007:117).  
 
1.6.7.2 Statistical processing 
 
Descriptive statistics was used to summarize and describe the data in a concise form 
(Joubert 2007:137). The clinic records of all the clients who commenced IPT between 
01 July 2010 and 30 November 2011 and met the inclusion criteria were analysed. Their 
records up to 15-30 months of commencing IPT were followed and the proportion of 
those diagnosed with TB before the end of that period was indicated. The percentage of 
the participants who were male or female and the percentage of patients who adhered 
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to their medications and those who did not go to the clinic to collect the full 6-month 
course of IPT were analysed.   
 
Analysis of the data was done using the Statistical Package for the Social Sciences 
(SPSS). The test statistic was calculated by applying the appropriate statistical formula 
using the sample data collected from the study. Analysis was undertaken to measure 
the associations between intake of IPT and incidence of TB among the study 
participants with the assistance of a statistician.  
 
1.6.8 Validity and reliability 
 
The quality of a research instrument is determined by its validity and reliability (see 
chapter 3). 
 
1.6.8.1 Reliability of the data-collection instrument 
 
Reliability is the extent to which measures are consistent or repeatable over time (Brink 
et al 2012:157). The reliability of the instrument is the consistency with which it 
measures the target attributes (Polit & Beck 2012:331). It was assumed that the 
precision and sensitivity of the laboratory equipment used in conducting HIV screening, 
TB and CD4 testing had been taken care of by the relevant authorities at National 
Health Laboratory Service at Stanger Provincial Hospital. Thus repeated administration 
of the data-collection instrument was not expected to change the responses from the 
records. The file clerk, data capturer and ART nursing staff assisted in retrieving the 
clinic records of the identified patients. They were not remunerated though the 
researcher provided them with refreshments. The data entries were made solely by the 
researcher. This ensured reliable data capturing. 
 
1.6.8.2 Measures to ensure validity 
 
Polit and Beck (2012:336) describe validity as “the degree to which an instrument 
measures what it is supposed to measure”. In this study, the researcher applied face, 
content, construct and criterion validity (see table 3.9). 
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1.6.8.2.1 Internal validity 
 
In order to ensure internal validity, the researcher made every effort to reduce bias, 
including selection and information bias. Efforts were made to avoid any form of bias 
that could invalidate the results of the study. A biased study result suggests one that 
does not represent the truth (Myer & Karim 2007:160). The researcher under guidance 
from the supervisor as well as a scientific committee in the Department of Health 
Studies at UNISA checked the data- collection instrument before commencing the 
study. Similar responses should be expected to ensure internal validity of the collection 
instrument. 
 
The clinic records of the clients who received IPT within the indicated period and met 
the selection criteria were utilised for the study. This eliminated selection bias as 
sampling was not used to select the clinic records used for the study. All the records 
that fulfilled the requirements were used. 
 
Information bias was avoided by ensuring that the variables are measured in the same 
way (Myer & Karim 2007:163). The researcher who collated the data did not have a 
working knowledge about the participants. Prior to data analysis, the District Data 
Coordinator was approached to cross-check the entries made. 
 
1.6.8.2.2 External validity 
 
External validity refers to the extent to which study findings can be generalised beyond 
the sample used in the study (Grove et al 2013:202). Polit and Beck (2012:250) indicate 
that external validity concerns the extent to which it can be inferred that the research 
findings hold true over variations in people, conditions and settings. Due to the study 
population which was far less than the population of South African adults that received 
IPT and the difference in the study setting when compared to other areas of the country, 
the results of the study cannot be generalised to the entire population of adults aged 
over 18 that received IPT from other centres in the country. However, in patients that 
access care in areas with similar developmental status in the province, the outcome of 
the study can be generalised to them. 
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1.6.9 Ethical considerations 
 
Ethics deals with matters of right and wrong. Ethical considerations are essential to the 
design of any research involving human subjects in order to protect the rights of the 
participants.  
 
Ethical approval for the study was obtained from the Higher Degrees Committee of the 
Department of Health Studies (Research Ethics Committee), University of South Africa 
(see Annexure D). Permission for the study was also obtained from the KwaZulu-Natal 
Department of Health, iLembe District Department of Health and the Management of 
Isithebe Clinic before embarking on the study (see Annexures C and E). In order to 
maintain anonymity and confidentiality, the actual names of the participants whose 
records were used for the study were not indicated in the data-collection sheet. In place 
of the actual names, a code was used for identification. All the documents relating to the 
study will be stored away from public access for at least five years. The electronic data 
will be password-protected to ensure denial of access to the data by unauthorised 
individuals.   
 
1.7 SCOPE OF THE STUDY 
 
The study focused on the adult HIV-positive clients that received IPT in Isithebe Clinic 
between July 2010 and November 2011. The findings of the study will be used to 
describe their demographic characteristics and the incidence of TB among those who 
completed IPT. The defaulter rate to IPT was also ascertained. 
 
1.8 SIGNIFICANCE OF THE STUDY 
 
The outcome of the study will be shared with the relevant stakeholders including the 
facilities where the study was conducted, the District and the provincial department of 
Health. It is expected that this will encourage clinicians working at the various clinics to 
intensify the use of IPT as a form of protection against TB infection. This is important 
since no known scientific study has been carried out in iLembe regarding the efficacy of 
IPT. Strategies aimed at controlling TB among HIV-positive clients that will be 
recommended to the health authorities will assist in strengthening existing IPT policy. It 
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is envisaged that the findings of the study when shared with HIV-positive patients will 
further encourage them to accept IPT and ensure adherence to the medication.  
1.9 DEFINITION OF CONCEPTS 
 
Acquired Immune Deficiency Syndrome (AIDS) 
 
AIDS refers to the symptoms and sicknesses that people infected with human 
immunodeficiency virus (HIV) eventually develop because of their weakened immune 
systems (Wilkins 2010:386).  
 
Viral load 
 
Viral load means the concentration of HIV ribonucleic acid (RNA) in the blood plasma 
(Wilson, Cotton, Bekker, Meyers, Venter & Maartens 2008:48). It indicates how much 
HIV there is in the blood, how quickly it is replicating, and how quickly a patient is 
progressing towards AIDS and subsequent death.  
 
CD4+ cells 
 
CD4+ cells refer to those T-lymphocyte components of white blood cells that are directly 
and indirectly destroyed by HIV (Wilson et al 2008:49). Wilson et al (2008:49) further 
indicate that the CD4+ cells play a central stimulatory role in the immune system and 
their count indicates the stage of the disease. When their numbers fall due to the 
exhaustion of the regenerative capacity of the immune system occasioned by prolonged 
destruction by HIV, the affected individual is suppressed immunologically.  
 
Adherence 
 
Haynes, Ackloo, Sahota, McDonald and Yao (2005:2) define adherence as how patients 
follow the instructions they are given regarding intake of prescribed treatments. 
Zuurmond (2008:5) describes adherence as taking the doses of drugs and sticking to 
the treatment plan thus taking the correct dose of drugs at the correct time and in the 
correct way.  
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Adult 
 
Adult means a fully grown person who is legally responsible for their actions (Oxford 
Advanced Learner’s Dictionary 2010a:20).  
 
Antiretroviral therapy 
 
Antiretroviral therapy refers to the use of at least 3 drugs in combination in order to keep 
viral load suppressed (Wilson et al 2008:469). Wilson et al (2008:469) add that the 
therapy is life-long as it reverses the progression of HIV disease by reducing the HIV 
viral load in the blood and does not cure HIV. Treatment-naive patients are usually 
initiated on triple therapy, which consists of one non-nucleoside reverse transcriptase 
inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitor (NRTI) in 
combination (NDOH 2010c:13).  The NDOH (2010c:20) further indicates that a third 
class of drug known as protease inhibitor (PI) is introduced to replace the NNRTI as part 
of the second-line treatment for patients failing first-line regimen. 
 
Human Immunodeficiency Virus (HIV) 
 
HIV is a single-stranded ribonucleic acid (RNA) retrovirus of the Lentivirus family that 
causes AIDS. After mucosal exposure, the virus infects the CD4 cell resulting in the 
attrition of the CD4 cell population which are pivotal in orchestrating the immune system 
of the body.  The depletion of the CD4 cells renders the body susceptible to various 
opportunistic infections (Wilkins 2010:387).  
 
Isoniazid preventive therapy (IPT) 
 
This refers to the intake of isoniazid by individuals with latent infection with 
Mycobacterium tuberculosis in order to prevent the progression to active TB disease 
(FPD 2010b:127). Isoniazid is a drug used in the treatment of TB when combined with 
other drugs and for prophylaxis of TB when used alone (SAMF 2010:317). 
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Tuberculosis (TB) 
 
Tuberculosis is an infectious disease caused by infection with a microorganism called 
Mycobacterium tuberculosis (Reid 2010:688). Mycobacterium tuberculosis is spread by 
the inhalation of aerosolised droplet nuclei from other infected patients.  
 
Incidence 
 
The incidence of a disease represents the rate of occurrence of new cases arising in a 
given period in a given population at a given point in time (Bonita, Beaglehole & 
Kjellström 2006:18). 
 
Demographic characteristics 
 
Demographic characteristics refer to the features of populations and include all aspects 
of population structure and changes which can be measured numerically (Joubert & 
Ehrlich 2007:24).  
 
1.10 OPERATIONAL DEFINITION OF CONCEPTS 
 
Acquired Immune Deficiency Syndrome (AIDS) 
 
Where the records used for the study indicated AIDS, it meant that the patient had 
symptoms and sicknesses that people infected with human immunodeficiency virus 
(HIV) eventually develop because of their weakened immune systems (Wilkins 
2010:386).  
 
Viral load 
 
According to the South African guidelines which were used throughout the study, it is 
deemed undetectable when the count is less than 400 copies/mlof blood (NDOH 
2010c:19). 
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CD4+ cells 
 
The readings recorded for CD4 cell count were those reported by the National Health 
Laboratory Service in Stanger Hospital where the tests were done. 
 
Adherence 
 
A research participant whose record was utilized for the study was deemed to have 
adhered to a course of IPT if not more than one treatment interruption was recorded 
during treatment and the 6-month therapy was taken within a 9-month period (NDOH 
2010b:7). 
 
Adult 
 
For the purpose of the study, adult referred to the category of HIV patients who received 
IPT at Isithebe Clinic within the designated period who were 18 years and older.  
 
Antiretroviral therapy 
 
Antiretroviral therapy refers to the triple therapy, which consists of one non-nucleoside 
reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase 
inhibitor (NRTI) in combination, that was commenced on the patients for management 
of HIV disease (NDOH 2010c:13). The NDOH (2010c:20) indicates further that a third 
class of drug known as protease inhibitor (PI) is introduced to replace the NNRTI as part 
of the second-line treatment for patients failing first-line regimen. 
 
Human Immunodeficiency Virus (HIV) 
 
In the facility where the study was conducted, a patient was deemed to be positive for 
HIV if the initial ELISA test performed was positive and a second test with another 
ELISA from a different manufacturer was used to confirm the diagnosis and exclude 
possible technical errors (Regensberg & Dunn 2012:7). This practice is also available in 
other public health facilities in South Africa. 
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Isoniazid preventive therapy (IPT) 
 
IPT refers to the intake of 300 mg of isoniazid daily by individuals with latent infection 
with Mycobacterium tuberculosis in order to prevent the progression to active TB 
disease (FPD 2010b:127).  
 
Tuberculosis (TB) 
 
For the purpose of the study, a patient was said to be diagnosed with TB when the acid 
and alkaline fast bacilli (AAFB) was demonstrated directly in the sputum, based on the 
clinical presentation or by TB culture (FPD 2010a:65). 
 
Incidence 
 
Incidence in the context of this study implied the counting of the number of clients 
diagnosed with TB disease in the population of HIV clients who received IPT in Isithebe 
PHC clinic between July 2010 and February 2011 and were used for the study. 
 
Demographic characteristics 
 
The demographic characteristics that were recorded and measured during the course of 
the study are the sex, age of the accessible population that commenced IPT. 
 
 
1.11 STRUCTURE OF THE DISSERTATION 
 
Chapter 1 presents an overview of the study. 
 
Chapter 2 discusses the literature review on TB and HIV. 
 
Chapter 3 describes the research design and methodology. 
 
Chapter 4 covers the data analysis and interpretation, and results. 
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Chapter 5 concludes the study, briefly describes its significance and limitations and 
makes recommendations for practice and further research.  
 
1.12 CONCLUSION 
 
This chapter described the research problem, research design and methodology, 
significance and scope of the study, and ethical considerations and defined key 
concepts  
 
Chapter 2 discusses the literature review conducted for the study. 
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CHAPTER 2 
 
Literature review 
 
 
2.1 INTRODUCTION  
 
This chapter discusses the literature review on HIV/AIDS, TB, HIV/TB co-infection and 
TB preventive therapy conducted for the study. With the upsurge in the global TB 
burden, the greatest increase in terms of the incidence of TB disease was noted among 
the population of people with the highest HIV rates. Africa has the highest prevalence 
and mortality rate associated with TB disease (WHO 2013c:9). 
 
Literature indicates that HIV is the strongest risk factor recognised in the reactivation of 
latent or new Mycobacterium tuberculosis infection to active TB disease (FPD 2012:25; 
Wilson et al 2008:35). The researcher explored the literature to highlight the clinical 
features and current management guidelines of HIV, TB and TB preventive therapy. 
Various databases (Google scholar, Pubmed, Medline, WHO) were searched and the 
words tuberculosis, isoniazid preventive therapy, HIV/AIDS, adherence, MDR-TB, 
antiretroviral therapy and HIV infection were used to search for applicable literature. 
Relevant sections of Internal Medicine textbooks and reports/guidelines released by the 
National Department of Health, South Africa were also perused. 
 
2.2 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
 
Sub-Saharan Africa still bears an inordinate share of the global HIV burden (UNAIDS 
2010:25). Furthermore, although the rate of new HIV infections has decreased, the total 
number of people living with HIV in the region continues to rise. In 2009, that number 
reached 22.5 million which represents 68% of the global total which was estimated to be 
33.3 million at the end of 2009. Recent statistics indicate that there were more people 
living with HIV in 2011 than ever before due to expanding treatment access and 
subsequent declining death rates. Globally, this figure was put at 35.3 million in 2012 
(UNAIDS 2013:4). The UNAIDS also indicates that in sub-Saharan Africa where the 
need for treatment with antiretroviral therapy (ART) is the greatest, more than half the 
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people needing treatment, were receiving it in 2011, and 22% more people were 
receiving the treatment in 2011 than a year earlier. The number of deaths due to AIDS 
also decreased from an estimated 2.3 million in 2005 to about 1.6 million in 2012 
(UNAIDS 2013:4). 
 
South Africa has one of the largest Anti-Retroviral Therapy (ART) programmes in the 
world (Padayatchi, Naidoo, Dawood, Kharsany & Karim 2010:88) but in South Africa, 
having unprotected sex with multiple partners remains the greatest risk factor for HIV. 
With an estimated 5.575 million PLHIV in 2010 (NDOH 2011b) and about 6.1 million 
people in 2012, South Africa's epidemic remains the highest in the world followed by 
Nigeria with 3.4 million HIV-infected individuals and India with an estimated 2.1 million 
PLHIV (UNAIDS 2013:A15). The NDOH (2011b) further indicates that the national HIV 
prevalence estimate among antenatal women in 2010 was 30.2% while in KwaZulu-
Natal, the figure was 39.5%. KwaZulu-Natal province has consistently recorded the 
highest provincial HIV prevalence since 1990 (NDOH 2010a:43).  
 
In the iLembe district, where the study was conducted, the HIV prevalence was 42.3% 
in 2011 making it the district with the highest prevalence of HIV among antenatal 
women throughout the country (NDOH 2011b).  However, statistics from 2012 indicate 
that the prevalence had declined to 35.4% (NDOH 2012:17). The HIV prevalence for the 
entire iLembe population was 16.6% at the first quarter of 2011 (Enterprise iLembe 
[s.a.]:13). 
 
2.2.1 Pathogenesis of HIV 
 
HIV is a single-stranded RNA retrovirus from the genus lentivirus of the family 
retroviridae (Wilson et al 2008:16).  
 
Two types of HIV exist, namely: 
 
 HIV Type 1 (HIV-1): This type is responsible for the global pandemic. 
 HIV Type 2 (HIV-2): This type is less pathogenic than HIV-1. It exists mainly in 
West Africa with limited spread to other countries largely due to migration (Wilson 
et al 2008:16).  
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HIV 1 is morphologically similar to HIV2 but only differs in the course of the disease and 
treatment method in which case the transmission rate for HIV2 is usually lower 
compared to HIV1 (Tadoka & Kavathekar 2013:315). 
 
HIV-1 is a rapidly evolving virus with a high viral turnover due to the nature of the 
reverse transcriptase. The inherent ability of adapting rapidly enables it to develop drug 
resistance; escape detection by the immune system, and affect possible use of vaccine 
and accurate diagnosis using viral assays (Wilson et al 2008:16). 
 
Upon entry into a cell mainly through mucosal exposure, HIV is transported to the lymph 
nodes via dendritic CD4 T lymphocytes or Langerhans cells where infection becomes 
established (Wilkins 2010:387). Also referred to as T-helper cells, the CD4 T 
lymphocytes are white blood cells that are an essential part of the human immune 
system that send signals to other types of immune cells like CD8 cells to destroy the 
infecting virus. The gut-associated lymphoid tissue also plays a major role in the 
establishment of infection and initial depletion of the memory CD4 T cells (Fauci 
2009:601). Fauci indicates further that the hallmark of HIV disease is the 
immunodeficiency that results from a progressive deficiency of the CD4 cells. This 
occurs following failure of the host immunity system to control viral replications. The 
replications occur when the viral RNA genome is transcribed into double-stranded DNA 
by a virally encoded reverse transcriptase that is present in the HIV particle. The 
resultant viral DNA migrates to the cell nucleus and integrates into the host cell (Manda 
2009:35). HIV transmission is also influenced by the viral load of the infected person. 
 
2.2.2 Transmission of HIV 
 
Transmission of HIV infection is dependent on the viral load which determines the 
degree of infectiousness of the HIV-infected individual and susceptibility of the 
uninfected partner, especially during acute HIV infection (Kamps & Hoffman 2007:24). 
Viral load, phenotypic factors, and the existence of co-infections like sexually 
transmitted infections (STIs) affect the degree of infectiousness while hereditary, innate 
or acquired resistance in addition to existence of co-infections like TB affect the 
susceptibility of an individual to contracting HIV (Naicker 2010:1).  
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HIV is present in the blood and other body fluids, such as breast milk, semen, vaginal 
fluid and saliva. Individuals can contract HIV which eventually results in AIDS through 
various ways as described below. 
 
2.2.2.1 Unprotected sexual practices 
 
HIV could be transmitted through sexual practices like oral, anal, homosexual and 
heterosexual intercourse when done in an unprotected manner. HIV transmission 
through unprotected heterosexual intercourse is the leading mode of HIV infection 
worldwide (Simon, Ho & Karim 2006:490). The presence of STIs, especially genital 
ulcer, cervical atrophy, non-circumcision, and rectal or vaginal trauma, menstruation 
and increased number of partners increases the chances of HIV infection (Wilkins 
2010:387). The spread of HIV through unprotected sexual practices is determined 
largely by the viral load of the individual and breach of the genital mucosal barrier. This 
is because the plasma viral load in HIV-infected individuals correlates with the HIV load 
shed in genital secretions (Galvin & Cohen 2004:3). Therefore with higher plasma viral 
load, there is an increased likelihood of spreading HIV. Also, the breach in genital 
mucosal barrier that occurs as a result of genital trauma and STIs increases 
susceptibility of individuals to HIV. This is because areas of inflammation as a result of 
ulcer render the mucosa more susceptible to viral entrance as they provide direct 
entrance for the virus into the bloodstream and the CD4 cells attracted to the areas 
following the inflammation render the area more susceptible since the virus is attached 
to CD4 cells (FPD 2012:17). Sexually transmitted infections in both men and women 
have also been associated with increased genital viral shedding (Galvin & Cohen 
2004:3). 
 
2.2.2.2 Parenteral transmission 
 
Parenteral transmission results from blood/body fluid contact during unsafe blood 
transfusion, injection drug use and occupational injuries (FPD 2012:16). The risk of 
contracting HIV following a single transfusion of blood from an infected individual is 
100% (FPD 2012:15). Increased frequencies of injection drug use increases 
susceptibility to HIV infection. Also, healthcare workers and laboratory personnel could 
be infected by HIV while at work with HIV-infected specimens through occupational 
injuries (Fauci 2009:601). 
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2.2.2.3 Mother-to-child transmission (MTCT) 
 
Mother-to-child transmission of HIV can occur during pregnancy, childbirth or 
breastfeeding. Prolonged rupture of membranes, foetal trauma, aggressive suctioning of 
the baby that could breach the oral mucosa and chorioamnionitis increase perinatal 
transmission of HIV (Wilkins 2010:387). Breastfeeding accounted for about 360 000 
cases of HIV infection in 2005 globally and thus is an important route for MTCT of HIV 
(Coovadia, Rollins, Bland, Little, Coutsoudis, Bennish & Newell 2007:1107). About 25-
45% of infants born to HIV-infected breastfeeding women could be infected with HIV-1 
and exclusive breastfeeding with instant weaning after 3-6 months has been found to 
make breastfeeding safer (Thior, Lockman, Smeaton, Shapiro, Wester, Heyman, 
Gilbert, Stevens, Peter, Kim, Van Widenfelt, Moffat, Ndase, Arimi, Kebaabetswe, 
Mazonde, Makhema, McIntosh, Novitsky, Lee, Marlink, Lagahos & Essex 2006:794). 
Avoidance of breastfeeding prevents transmission of HIV from mother to her baby 
through breastfeeding. However, the use of infant formula especially where access to 
clean water is not guaranteed at all times is associated with increased infant morbidity 
and mortality (Thior et al 2006:795). The risk of perinatal HIV transmission was also 
noted to be lower with exclusive breastfeeding when compared with mixed feeding as 
the latter could lead to breach in the gut epithelium of the baby (Coovadia et al 
2007:1113). The presence of high viral load in the mother, which occurs in advanced 
AIDS or during the seroconversion period, increases the rate of HIV transmission from 
an infected mother to her baby. The rate is further increased with longer duration of 
breastfeeding, mastitis, and poor breast feeding techniques like poor latching (Wilkins 
2010:387). 
 
2.2.3 Diagnosis of HIV 
 
Laboratory diagnosis of HIV has evolved from detecting antibodies of the virus in the 
blood sample to viral RNA/DNA tests and viral culture which is largely used in reference 
laboratories for research (Wilson et al 2010:45). In South Africa, the NDOH 
recommends that people should test for HIV at least on an annual basis. Provider 
Initiated Counselling and Testing (PICT) for HIV is recommended to be offered to every 
individual accessing care in all healthcare settings unless the patient opts out. This is in 
line with the recommendations of the WHO that HIV testing and counselling should be 
offered as part of package of care to everyone seen in the health facilities in areas with 
 
22 
generalised epidemics (WHO 2013a:70). The US Centres for Disease Control and 
Prevention (CDC) recommends that healthcare providers should offer assessment care 
to all patients at health facilities for voluntary screening of HIV (Mahajan, Stemple, 
Shapiro, King & Cuuningham, 2009:264). However, in areas of concentrated or low-
level epidemics, the WHO (2013a:70) recommends that HIV testing and counselling 
should be offered to those presenting to health facilities with signs and symptoms 
suggestive of underlying HIV infection. HIV-exposed children are also to be counselled 
and tested for HIV. 
 
The three testing strategies recommended by the UNAIDS and the WHO for use in 
screening serum or plasma sample are as follows: 
 
Strategy I: Strategy I is recommended for the use in screening blood or body organs 
meant for donation, surveillance in areas of >10% HIV prevalence and diagnosis of HIV 
in areas where HIV prevalence is >30% (WHO 2004:6). In this strategy, each serum 
sample is tested with one ELISA or rapid assay. The serum that tests positive is 
considered HIV antibody positive while the one that tests negative is considered HIV 
antibody negative. 
 
Strategy II: As illustrated in Table 2.1, strategy II is recommended for use in diagnosing 
individuals with HIV clinical stage III or IV infection in areas where HIV prevalence 
<30% as defined by the WHO (WHO 2007b:15). Other scenarios where the use of 
strategy II is recommended are for surveillance where HIV prevalence is ≤10% and HIV 
screening for asymptomatic individuals in areas where the prevalence in the population 
is >10%.  
 
In this strategy, the serum/plasma sample is initially tested with ELISA or rapid assay 
with subsequent retesting using a different ELISA or rapid test kit if the result is positive. 
If the result is positive on both tests, the patient is diagnosed as HIV positive. However, 
if discordant results are noted, the sample is re-tested by either ELISA or rapid assay 
and if concordant results are noted, it is accepted. When the results remain discordant 
after the retesting, the test is deemed indeterminate. The WHO (2004:6) recommends 
repeat testing after two weeks for indeterminate results in asymptomatic individuals and 
further confirmatory testing if the results remain indeterminate. Discordant results are 
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accepted as positive if the individual tested has clinical features indicative of HIV 
Clinical stage III or IV (WHO 2007:16). 
 
Strategy III: Strategy III is recommended for use in screening individuals where 
prevalence of HIV infection is ≤10%. According to the WHO (2004:5), any reactive 
sample noted using the ELISA or rapid assay is retested using a different assay. While 
the serum that is negative is not disputed, the reactive sample is retested using both 
tests and if positive, a third test is carried out. The test is considered HIV antibody 
positive if reactive on all the three samples while the serum that remains discordant in 
the second assay or is reactive in the first and second test but negative on the third test 
is considered as an indeterminate result.  
 
Table 2.1 HIV testing strategies 
 
Objective of testing 
Prevalences of 
infection 
Testing strategy 
Transfusion/transplant safety All prevalences I 
Surveillance 
>10% I 
≤10% II 
Diagnosis 
Clinical 
signs/symptoms of 
HIV infection 
>30% I 
≤30% II 
Asymptomatic 
>10% II 
≤10% III 
 
(WHO 2004:3) 
 
The standard laboratory test in South Africa is the Enzyme Linked Immunosorbent 
Assay (ELISA) which is about 99.5% sensitive in patients infected with HIV for more 
than 3 months already (Barlett et al 2008:8). According to the HIV testing algorithm 
recommended by the NDOH (2010d:23), a rapid test is used to test the blood sample of 
the individual. If the screening result is non-reactive, the result is reported as negative 
while if the result is positive, a second rapid test from a different manufacturer is used 
for HIV testing with a follow-up ELISA test if negative after the initial positive result. The 
test is considered HIV antibody reactive if positive following the ELISA test. However, if 
the ELISA is non-reactive, the client is encouraged to live a risk-free life and retest after 
three months to exclude possibility of a window period. A window period refers to the 
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period when an individual has not developed antibodies to HIV in the body fluid even 
though HIV infection has taken place. It could be as early as four weeks (Wilson et al 
2009:46) and rarely exceeds six months (Barlett et al 2008:8). 
 
Despite the high sensitivity and specificity of the ELISA test, there are instances where 
the test result could be incorrect. False negative test results using the ELISA are 
commonly due to errors committed while carrying out the test or writing up the results 
and also occur if the test was performed during the window period when the patient has 
not seroconverted. That explains why individuals with negative antibody test results are 
advised on risk-free living and repeat of HIV test after three months. However, the 
presence of auto antibodies, use of HIV vaccines, erroneous reporting of HIV infection 
with intention to deceive and influenza vaccination are capable of causing false positive 
results (Barlett et al 2008:9). 
 
The Western blot test could also be used as a confirmatory after ELISA. It detects 
antibodies to HIV antigens of specific molecular weights (Fauci 2009:603). With the 
advent of reliable ELISA tests, Western blot is not currently used routinely for the 
confirmation of HIV infection in the public healthcare system of South Africa due to cost 
concerns and improvements in the sensitivity and specificity of ELISA tests. 
Nevertheless, it remains the most reliable confirmatory test for infection with HIV-2 
(Wilson et al 2008:44).  
 
Fauci (2009:603) points out that the use of polymerase chain reaction (PCR), branched 
DNA nucleic-acid based assay (NABBA) or viral culture can detect HIV infection during 
the window period and beyond. The PCR test could detect a single copy of HIV nucleic 
acid in the blood sample hence the increasing use of this method for babies who still 
have their mothers’ antibodies circulating in their blood and by transfusion services. HIV 
can also be grown in cell culture in which case mononuclear cells from the peripheral 
blood of uninfected donor are incubated with the sample for testing (Wilson et al 
2008:45). Routine testing of HIV using PCR and viral culture is not practised on a large 
scale due to cost factors. The viral culture is largely used for research in reference 
laboratories (Wilson et al 2008:45). 
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2.2.4 Clinical progression of HIV disease 
 
2.2.4.1 Acute HIV infection 
 
Acute HIV infection refers to the initial period following HIV infection, usually within the 
first 30 days (Naicker 2010:1). In order for infection to become established, HIV needs 
to cross the epithelial barrier and come into contact with CD4+ immune cells with CCR5 
or CXCR4 chemokine receptors (Wilson et al 2008:55).  The presence of genital 
trauma, ulceration or inflammation in addition to the viral load from the source HIV-
positive individual enhances HIV infection in both partners (FPD 2012:17; Wilkins 
2010:387) (see section 2.2.2 for modes of HIV transmission).  
 
Immune activation during HIV infection is a major contributor to disease progression 
and is the product of inflammatory responses to HIV-encoded receptors, microbial 
translocation and homeostatic response to CD4+ T-cell depletion. Immune cells 
activated during HIV infection include T cells, B cells, natural killer cells, macrophages 
and plasma cytokines. IL-7, IL-12p40, IL-12p70, IFN-У and IL-15 are the types of 
plasma cytokines noted in women with acute infection that have been found to be 
predictive of long-term HIV disease prognosis (Roberts, Passmore, Williamson, Little, 
Bebell, Mlisana, Burgers, Van Loggerenberg, Walzl, Djoba Jiawaya, Abdool Karim & 
Abdool Karim 2010:821). Roberts et al (2010:821) point out that HIV viral loads in 
plasma and systemic CD4 counts are the widely accepted predictors of HIV disease 
progression though T-cell proliferative capacity and concentrations of soluble 
biomarkers such as TNF-rIL, neopterin and β²-microglobulin during chronic infection 
have also been shown to predict HIV disease progression to AIDS. Neopterin is one of 
the chemicals synthesised by human macrophages during HIV infection and because 
their concentrations usually correlate with the extent and activity of HIV, they are used 
as monitors of the disease progression (Murr, Widner, Wirleitner & Fuchs 2002:175).  
 
Primary infection with HIV could be symptomatic in 70-80% of cases within the first six 
weeks of infection (Wilkins 2010:389). In about 80% of infected individuals, acute HIV 1 
infection is symptomatic (Manda 2009:38). Early HIV infection is characterised by the 
appearance of viral markers and antibodies in the blood (Cohen, Shaw, McMichael & 
Haynes 2011:1944). Symptoms at this stage may include fever, influenza-like illness, 
sore throat, rash, myalgia, mouth sores, and lymphadenopathy among others. 
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Recognition of HIV infection is important as the initial viraemia makes the infected 
individual highly infectious and HIV transmission readily occurs within this period. 
However, in practice, most of the infections at this stage are undiagnosed as the routine 
antibody tests are negative due to the delay in the production of antibodies to HIV 
during the acute HIV infection stage. Worldwide, only about 1000 cases have been 
diagnosed during the first month of infection (Naicker 2010:1). Naicker (2010:1) further 
indicates that only viral specific diagnostic tests like HIV nucleic acid amplification assay 
are needed to diagnose the infection prior to the appearance of HIV antibodies. The p24 
antigen test is about 89% sensitive, 100% specific and detects HIV infection as early as 
2 weeks after infection. However, due to cost factors, the p24 test is not routinely 
available in the public health system of South Africa. 
 
As depicted in figure 2.1, there is a marked increase in the viral load and sharp decline 
in CD4 count during this stage. The use of antiretroviral therapy effectively reduces the 
viral load and slows down extensive damage to the immune system during this period 
(Hecht, Wang, Collier, Little, Markowitz, Margolick, Kilby, Daar, Conway & Holte 
2006:726). This forms the basis of the use of antiretroviral in post exposure prophylaxis. 
 
2.2.4.2 Asymptomatic stage 
 
The asymptomatic stage refers to the period during which the infected patient largely 
remains well and does not manifest clinical features of retroviral disease except for the 
occasional occurrence of persistent generalised lymphadenopathy (Wilkins 2010:389). 
Without the use of ART, this period could last between 2->20 years and is characterised 
by CD4 decline and viral replication (Naicker 2010:2). Faster progression to CD4+ cell 
count of 350 cells/µL or less, viral load of at least 1x100000 copies/ml and AIDS has 
been observed in HIV-1 subtype C when compared to subtypes A and D (Amornkul, 
Karita, Kanali, Rida, Sanders, Lakhi, Price, Kilembe, Cormier, Anzata, Latka, Bekker, 
Allen, Gilmour & Fast 2013:2283). This stage is also known as the clinical latency 
period and is illustrated in figure 2.1. There is progressive decline in CD4 count and 
gradual increase in viral load. The rate at which these occur could vary from one patient 
to another. 
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2.2.4.3 Mildly symptomatic disease stage  
 
The mildly symptomatic disease stage refers to the period in the majority of patients 
infected with HIV that is characterised by some impairment of cellular immunity which 
are not AIDS defining (Wilkins 2010:390). Wilkins (2010:390) further indicates that while 
some patients could be fast or slow progressors, the average interval from infection to 
the development of symptoms is around 7-10 years.  
 
Symptoms or disease states like recurrent oropharyngeal or vaginal candidiasis, pelvic 
inflammatory diseases (PID), herpes zoster, chronic diarrhoea, peripheral neuropathy, 
weight loss and fever could occur during this period with sustained increase in viral load 
(FPD 2012:81). 
 
 
 
Figure 2.1   Natural history of HIV infection 
(Wilson et al 2008:57) 
 
2.2.4.4 Advanced HIV disease stage 
 
Advanced HIV disease stage is also referred to as Acquired Immunodeficiency 
Syndrome (AIDS). This stage occurs in untreated patients or patients with virological 
failure (Fauci 2009:602). Specific AIDS-defining opportunistic infections, tumours or 
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presentations occur within this period with decline of CD4+ cell count to levels lower 
than 200/µL and increase in viral load. This stage is depicted in figure 2.1. 
 
Disease states such as oesophageal candidiasis, meningitis, cerebral toxoplasmosis, 
CMV retinitis, tuberculosis, pneumocystis jirovecii pneumonia, karposi sarcoma, 
lymphoma, invasive cervical cancer amongst others could occur within this period 
(Wilkins 2010:390). If left untreated, death ultimately occurs. However, drugs have been 
developed for the treatment of HIV infection and AIDS. 
 
2.2.5 Treatment of HIV infection 
 
The use of antiretroviral treatment (ART) for the management of HIV and AIDS 
decreases morbidity, mortality and improves the quality of life for many patients all over 
the world (Formundam & Mathews 2009:2). ART programmes in the developing world 
where free medication is provided, such as in South Africa, have been found to be 
effective with viral load suppression rates similar to figures noted in developed countries 
(Ivers, Kendrick & Doucette 2005:223). In the absence of antiretroviral treatment, HIV 
infection progresses to AIDS at a medium time of 8-10 years with the median survival 
time after developing AIDS significantly reduced to only 9.2 months (Kamps & Hoffmann 
2007:24).  
 
South Africa has one of the largest ART programmes in the world and provides the 
medication free of charge to eligible patients across all public health institutions in the 
country (Padayatchi, Naidoo, Dawood, Kharsany & Karim 2010:88). 
 
The WHO (2013a) provides consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection in susceptible individuals. The NDOH (2013a) 
developed clinical guidelines for the management of HIV and AIDS in adults and 
adolescents for South Africa. In addition to several goals, the objectives of the 
programme are to contribute to strengthening of the public and private health sectors’ 
capacity to deliver high quality integrated health and wellness services; ensure timely 
initiation of antiretroviral drugs (ARVs) for treatment and prevention according to the 
Presidential mandates, and minimise unnecessary drug toxicities (NDOH 2013a:4). 
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2.2.5.1 Eligibility criteria for starting ART regimens for adults and adolescents 
 
Adults diagnosed with HIV in South Africa are eligible for commencement on ART if 
their CD4 count is ≤350cells/mm³, irrespective of the WHO clinical stage (NDOH, 
2013a:5). The ART treatment protocol is largely based on the recommendations by the 
WHO (2010c:20) that all adolescents and adults with CD4 count ≤350 cells/mm³ should 
start ARV irrespective of the existence of clinical symptoms. The NDOH emphasises 
that patients who are pregnant or breastfeeding are eligible to start ART, irrespective of 
their CD4 count. This also applies to patients with WHO clinical stage 3 or 4 including 
those co-infected with any form of TB or cryptococcal meningitis.  
 
Although the focus of the study is on HIV-infected individuals that were commenced on 
IPT, commencing those with TB on ART has been found to be associated with improved 
treatment outcomes as TB infection leads to high mortality in HIV-infected individuals 
(Karim, Naidoo, Grobler, Padayatchi, Baxter, Gray, Gengiah, Nair, Bamber, Singh, 
Khan, Pienaar, El-Sadr, Friedland & Karim 2010:702).  
 
The NDOH treatment guidelines differ from the current recommendations by the WHO 
on when to start ART in adults and adolescents. According to WHO (2013a:28), in 
addition to those eligible for treatment under the South African guidelines, ART should 
be initiated in all individuals with CD4 count ≤500cells/mm³ regardless of WHO clinical 
stage. Serodiscordant couples are also to be commenced on ART to reduce HIV 
transmission to the uninfected partners. 
 
However, patients who are not yet eligible for ART after clinical and laboratory 
assessments are transferred to a wellness programme for regular follow-up and repeat 
clinical assessment/CD4 count testing every six months according to the NDOH 
guidelines.  They are also advised on how to avoid HIV transmission to sexual partners 
and children, initiated on isoniazid (INH) prophylaxis if asymptomatic for TB and offered 
contraception and a pap smear (NDOH 2010:6). Initiation on INH is after screening 
using the screening tool and ascertaining that the patient is not a TB suspect. 
 
Table 2.2 describes the national ART regimen for adults and adolescents in South 
Africa. Once eligible for commencement on ART, all new adult patients are commenced 
on the fixed dose combination preparation (FDC) which contains Tenofovir, 
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Emtricitabine and Efavirenz except where there is contraindication to the use of any of 
them. When virological failure is diagnosed, the appropriate second- line regimen is 
used as outlined in table 2.2. Referral to HIV treatment specialist is advised where there 
is resistance to the second-line regimen.  
 
Table 2.2   Standardised National ART regimens for adults and adolescents 
 
1
st
 Line 
All new patients needing 
treatment including pregnant 
women 
TDF+FTC (or 3TC) + 
EFV 
FDC preferred 
Replace EFV with NVP in patients with 
significant psychiatric co-morbidity or 
intolerance to EFV and where the 
neuro-psychiatric toxicity of EFV may 
impair daily functioning e.g. shift 
workers. 
Contraindications to EFV 
 
TDF + (FTC or 3TC) + 
NVP 
Use NVP-based regimen: In patients 
with significant psychiatric comorbidity 
or intolerance to EFV and where the 
neuro-psychiatric toxicity of EFV may 
impair daily functioning e.g. shift 
workers  
 
Contraindication to TDF AZT + 3TC+ EFV (or 
NVP) 
Renal disease or the use of other 
nephrotoxic drugs e.g. amino-
glycosides  
Contraindication to TDF and 
AZT 
 
d4T+ 3TC +EFV (or 
NVP) 
 
Renal disease and anaemia or the use 
of other nephrotoxic drugs, 
aminoglycosides 
Contraindication to TDF, AZT 
and d4T 
 
ABC + 3TC+ EFV (or 
NVP) 
Renal disease, anaemia, peripheral 
neuropathy, the use of other 
nephrotoxic drugs. 
 
Currently on d4T-based 
regimen 
TDF + FTC (or 3TC) + 
EFV 
FTC preferred 
Mandatory if patients experience 
toxicity and patients who are at high 
risk of toxicity (high BMI or pregnant). 
Switch to TDF if virally suppressed and 
the patient has normal creatinine 
clearance, even if well tolerated. 
 
2
nd
 Line 
Management of virological 
failure 
 If plasma HIV RNA >1000 copies, 
check for adherence, compliance, 
tolerability and drug-drug interaction 
and assess psychological issues. 
Repeat VL test 2 months later 
If plasma VL confirmed >1000 copies, 
change regimen to second line therapy 
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Failing on a TDF-based 1st line 
regimen 
 
AZT + 3TC + LPV/r Patients with anaemia and renal failure 
switch to ABC 
 
Failing on a d4T-based 1
st
 line 
regimen 
TDF+3TC (or FTC ) and 
LPV/r 
 
 
 
Dyslipidaemia or diarrhoea 
associated with LPV/r 
Switch LPV/r to ATV/r  
 
 
3
rd
 Line 
Failing any 2nd line 
regimen 
 
Specialist referral  
 
 
Should be expert and genotype 
resistance testing based 
decision and supervised care. 
Patients failing on second line 
therapy will be managed by an 
expert panel. The drugs for third 
line will be managed centrally 
.More discussion is required to 
deal with the modalities 
Most likely regimen 
would be 
Raltegravir/Darunavir/ 
Etravirine adjusted 
according to genotype 
interpretation. Should be 
by expert and take into 
account prior exposure 
and predictable 
mutations. 
 
 
(NDOH 2013a:6) 
KEY: 3TC-Lamivudine; d4T-Stavudine; ABC-Abacavir; ATV/r-Atazanavir/ritonavir; AZT-Zidovudine; EFV-
Efavirenz; FTC-Emtricitabine; LPV/r-Lopinavir/ritonavir; NVP-Nevirapine; RNA-Ribonucleic acid; VL-Viral 
load. 
 
2.2.5.2 Standardised monitoring of clients on ART 
 
Table 2.3 indicates the standardised monitoring procedures for HIV-positive patients at 
the initial diagnosis of HIV, at routine follow-up visits, and when they are eligible for ART 
as outlined in the 2013 Clinical guidelines for the management of HIV & AIDS in adults 
and adolescents. The entire essence is to ensure best possible and timely care to 
deserving clients. Compared to previous editions, the 2013 guideline emphasises early 
commencement of ART and change in the timing of CD4 count tests. As illustrated in 
table 2.3, after initiation on ART, CD4 count follow-up CD4 count test will now be done 
at 1 year on ART and then every 12 months as opposed to the 2010 guidelines that 
required CD4 tests to be done at six months, one year post-initiation and then yearly 
afterwards (NDOH 2010b:3).  
 
The NDOH (2013a:6) also recommends that viral load monitoring should be done first at 
6 months after initiation where it is expected to be undetectable (NDOH 2013a:6).  
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Repeat viral load is also to be done at 1 year after commencement on ART and yearly 
after wards should the values remain undetectable. Should the viral load result read 
more than 1000 copies/ml, however, the NDOH (2013a:5) recommends that adherence, 
tolerability and psychological issues should be carefully assessed and the test repeated 
after two months of providing adherence services to the affected client. Regimen 
change to second-line therapy is recommended if the viral load remains more than 1000 
copies/ml on repeating the test.  
 
Table 2.3  Standardised national monitoring for adults and adolescents with HIV 
 
At Initial Diagnosis of HIV  Purpose 
Confirm HIV result with rapid antibody 
test 
Ensure that national testing algorithm has been followed 
 
Do CD4 count if HIV positive and WHO 
clinical staging 
To assess eligibility for ART 
To assess eligibility for fast-tracking 
 
Screen for pregnancy or ask if planning 
to conceive 
To identify women who need ART for life  or ARV 
prophylaxis for PMTCT  
 
Screen for TB symptoms using the 
WHO questionnaire 
To identify TB/HIV co-infected 
 
Do the CD4 count on the same day To identify eligibility for ART or ARVs for prophylaxis if 
pregnant 
Do Hb or FBC if requires AZT 
 
Creatinine if requires TDF 
 
For patients initiated on Nevirapine 
based regimen, do ALT 
To detect anaemia or neutropenia 
 
To detect renal insufficiency 
 
To exclude liver disease 
On ART Purpose 
CD4 at 1 year on ART To monitor immune response to ART 
 
VL at month 6, 1 year on ART and then 
every 12 months 
To identify treatment failures and problems with adherence 
ALT only if on NVP and develops rash 
or symptoms of hepatitis 
To identify NVP toxicity 
FBC at month 3 and 6 if on AZT To identify AZT toxicity 
Creatinine at month 3 and 6, 1 year 
then every 12 months if on TDF 
To identify TDF toxicity 
Fasting cholesterol and triglycerides at 
month 3 if on LPV/r 
To identify LPV/r toxicity 
 
At Routine follow-up visits for those 
not yet eligible on ART 
Purpose 
 
Repeat CD4 at 6 months To see if they have become eligible for ART 
WHO clinical staging at every visit To see if they have become eligible for ART 
 
33 
Screen for TB symptoms to identify TB 
suspects 
 
Offer IPT if no TB symptoms 
To identify TB/HIV co-infection 
 
 
To prevent TB activation 
Offer prevention for HIV positives To prevent HIV transmission and re-infection 
To prevent STIs 
 
(NDOH 2013a:7) 
 
Screening for TB symptoms should also be done at every visit to any health facility. This 
is to identify TB/HIV co-infection and institute the appropriate management accordingly. 
Where no TB symptoms exist and the patient is eligible, Isoniazid preventive therapy 
(IPT) is commenced to avoid the activation of TB disease. 
 
2.3 TUBERCULOSIS 
 
Tuberculosis is caused by infection with tubercle bacillus known as Mycobacterium 
tuberculosis and can be spread by the inhalation of aerosolised droplet nuclei from 
other infected people (Reid, 2010:688). This was first demonstrated by Robert Koch in 
1882 (Foundation for Professional Development [FPD] 2010a:6). 
 
2.3.1 Pathology and pathogenesis of tuberculosis 
 
The organism that causes TB, Mycobacterium tuberculosis lodges in the alveoli once 
inhaled and thereafter commences the formation of macrophages and lymphocytes. 
The macrophages undergo transformation into epithelioid and Langhans cells. These 
merge with the lymphocytes to form tuberculous granuloma, also known as Ghon focus 
when lots of them aggregate together usually situated in the periphery of the lung. The 
hilar and paratracheal group of lymph nodes also harbour Ghon lesion (Barlam & 
Kasper 2009:538). The capsule that encases the lesions limits the spread of the bacilli 
resulting in latent TB infection.  
 
In situations where the defence system of the body is unable to contain the invading 
organisms, they multiply and eventually lyse the macrophages. This results in spread to 
the regional lymph nodes initially with the possibility of spreading throughout the body 
afterwards (Barlam & Kasper 2009:538). With lymphatic or haematological spread, 
these lesions could be lodged in other body organs like kidneys, lungs, lymph nodes, 
bones and liver where they may lie dormant for years. 
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Detection of infection at this stage is by the existence of delayed-type hyper- sensitivity 
reaction to tuberculin which is demonstrated by tuberculin skin testing (FPD 2010a:19). 
The failure of the aforementioned reparative processes leads to active TB disease. FPD 
further indicates that the lifetime risk of developing disease after primary infection is 
10% in the absence of HIV/AIDS which accelerates this process. 
 
2.3.2 Epidemiology of tuberculosis 
 
The FPD (2010a:5) indicate that TB existed in the world for centuries as an endemic 
disease among animals long before it affected humans, possibly existing in non-human 
primates. The incidence of TB had generally been on the decline in the world until the 
early 1980s when an increase of cases was reported in the USA, parts of South East 
Asia, East, Central, West and Southern Africa. While various factors contributed to the 
upsurge in the global TB burden, the groups with the greatest increase in TB were also 
the groups with the highest HIV rates (Balcells, Thomas, Godfrey-Faussett & Grant 
2006:744; FPD 2010a:31). 
 
From an estimated 7-8 million cases in 1993 when the WHO declared TB a global 
public health emergency, the spread of TB increased to about 8.6 million new cases in 
2012 (WHO 2013c:1). Table 2.4 indicates the estimated burden of disease caused by 
TB in South Africa and across the major regions of the world in 2011.  
 
Table 2.4 Estimated burden of disease caused by TB in 2011 
 
(Rates per 100 000 population) 
 
Population 
(thousand) 
Mortality Prevalence Incidence 
HIV prevalence in 
incident TB cases 
(%) 
Best Low High Best  Low High Best Low High Best Low High 
South 
Africa 
50 460 49 21 87 768 399 1250 993 819 1180 65 65 66 
Africa 857 382 26 21 31 293 243 347 262 242 283 39 37 41 
America 943 019 2.2 1.9 2.5 35 26 44 28 26 29 14 11 17 
EMR 608 628 16 10 24 170 108 246 109 97 122 1.5 0.9 21 
EUR 899 500 5.0 4.9 5.1 56 41 73 42 39 45 6.1 4.4 8.0 
SEAR 1 830 361 26 19 34 271 206 344 189 176 203 4.1 3.3 5.0 
WPR 1 808 797 6.9 5.7 8.3 138 123 154 92 84 100 2.2 1.4 3.1 
Global 6 947 687 14 12 17 170 150 192 125 120 130 13 12 14 
 
(WHO 2012:10)  
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Table 2.4 shows that the prevalence of TB disease is the highest in Africa. An estimated 
incidence rate of 262 per thousand was noted for Africa, which is high when compared 
to 42 recorded in Europe and other WHO-designated regions of the world. Africa also 
has the highest prevalence and mortality rate associated with TB disease as well as the 
highest HIV-positive incident TB cases (WHO 2012:9). The WHO (2011b:3) indicates 
that South Africa was among the five countries with the highest number of incident TB 
cases in 2010. South Africa is also one of the 22 high-burden countries that account for 
80% of all new TB cases globally and has the second highest TB incidence rate 
worldwide (Kranzer 2011:418). An estimated 0.40-0.59 million people were diagnosed 
with TB worldwide in 2010. Globally, TB is the second leading cause of death from an 
infectious disease after HIV accounting for an estimated 1.4 million deaths in 2012 
(WHO 2013c:1). About 300 000 deaths from TB recorded in 2012 occurred among 
people living with HIV (PLHIV).  
 
A total of 5,868 cases of TB were reported across all health facilities in iLembe, South 
Africa in 2012 (KZN Tuberculosis Programme, 2012). According to data released by the 
Tuberculosis programme, this figure includes all forms of TB across all segments of the 
population and 38.3% of the cases were smear positive.   
 
Various factors are associated with the risk of developing TB disease (FPD 2010a:14-
18). 
 
2.3.3 Risk factors for contracting tuberculosis 
 
The major factors that determine the risk of becoming exposed to the TB bacilli include 
the number of infectious cases in the community, the duration of their infectiousness 
and the number and nature of interactions between a TB case and a susceptible contact 
per unit time of infectiousness (FPD 2010b:19). FPD further indicates that the 
probability of becoming infected with Mycobacterium tuberculosis depends on the 
concentration of the infectious droplets in the air (infectious particle density) and the 
duration of exposure of a susceptible individual to the particle density.  
 
The risk of developing active TB following infection is largely endogenous and is 
determined by the integrity of the cellular system. This implies internal reactivation of 
the bacilli that has been latent after the initial infection (FPD 2010b:31). Reids and Innes 
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(2010:689) indicate that a history of close contact with any individual with smear-
positive pulmonary TB disease, prolonged infection with the TB bacilli, residence in 
poorly ventilated areas, extremes of age at which time immunity is low and co-infection 
with HIV/AIDS are some of the risk factors that accelerate the progression of primary 
infection to active TB disease. Other diseases like diabetes, silicosis, malignancies, 
renal failure, immunosuppressive states and malnutrition are also risk factors for 
development of active disease (FPD 2010a:16).  While increased population density 
and crowded living conditions noted in some urban areas increases transmission of TB 
disease, poor nutritional status and high HIV prevalence enhances the progression to 
active TB disease (Lӧnnroth, Jaramillo, Williams, Dye & Raviglione 2009:2241).  
 
2.3.4 Clinical features of TB disease  
 
The clinical features of TB disease include the various signs and symptoms associated 
with the disease and are discussed under the various forms of the disease.  
 
2.3.4.1 Primary pulmonary TB 
 
Primary pulmonary TB refers to the infection of a previously uninfected (tuberculin-
negative) individual. During this phase, a few patients develop a self-limiting febrile 
illness while the rest remain asymptomatic after the formation of the primary complex 
(tuberculous granuloma) described in section 2.3.1. The clinical feature at this stage is 
usually lymphadenopathy at the hilar and paratracheal areas that could be painless. 
However, in the immunocompromised individuals, like those living with HIV, 
spontaneous progression to clinical disease with cavitation and pleural effusions are 
common (Barlam & Kasper 2009:538).  
 
2.3.4.2 Post primary pulmonary TB 
 
Post pulmonary TB refers to exogenous or endogenous infection in a person who has 
been sensitised by an earlier exposure to tuberculous bacilli (Reid & Innes 2010:689). 
The onset is usually insidious and develops slowly over several weeks. Systemic 
symptoms include fever, night sweat, malaise, loss of appetite, loss of weight, chronic 
productive cough with occasional haemoptysis (Barlam & Kasper 2009:539). Reid and 
Innes (2010:689) further indicate that in extensive form of post primary pulmonary TB, 
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pleural effusion, spontaneous pneumothorax, and unresolved pneumonia could also be 
noted on examining the affected patient. 
 
2.3.4.3 Extra pulmonary TB disease 
 
Extra pulmonary tuberculosis (EPTB) refers to isolated occurrence of TB disease in any 
other part of the body apart from the lungs and accounts for more than 50% of all cases 
of TB in HIV-infected individuals (Sharma & Mohan 2004:316). Higher incidence of 
EPTB has been noted in USA since the AIDS epidemic occurred (Golden & Vikran 
2005:1761). Similar trends of rising rates of EPTB have also been reported in other 
countries of the world with HIV epidemics (WHO 2007:3). The clinical feature depends 
on the part of the body affected. Any part of the body could be affected with lymph node 
involvement occurring in more than 40% of the (EPTB) cases (Barlam & Kasper 
2009:539). Painless swelling of cervical, supraclavicular, axillary and inguinal group of 
lymph nodes are typical. The affected nodes, though initially mobile, could become 
matted with time and discharge through the skin with formation of abscess and sinus. 
 
Symptoms of abdominal TB include abdominal pain, diarrhoea, fever, night sweats, 
anorexia, weight loss, painful abdominal distension with exudative ascites. Extra 
pulmonary pericardial TB disease could occur in the form of pericardial effusion and 
constrictive pericarditis. The presentation is usually acute or sub-acute fever, dull 
retrosternal pain and pericardial effusion (Balaam & Kasper 2009:540). 
 
In the genitourinary diseases, urinary frequency, dysuria, haematuria and pyuria could 
occur (FPD 2010b:63).  Barlam and Kasper (2009:540) point out that the spine, hip and 
knees are the most common sites of skeletal TB disease. The vertebral bodies are 
affected in such cases with collapse of the vertebral bodies and resulting kyphosis and 
gibbous in extreme cases of the disease. 
 
Miliary disease refers to the form of TB caused by blood-borne spread of the 
tuberculous bacilli (Reid & Innes 2010:689). Reid and Innes emphasise that while 
miliary TB could present acutely, more frequently, it is characterised by fever, 
headache, night sweat, anorexia, weight loss and dry cough. Hepatosplenomegaly, 
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crackles, anaemia and appearance of small 1-2 mm lesions throughout the lung fields 
on chest X-ray are other clinical findings that are suggestive of military TB.  
 
Tuberculous meningitis occurs most often in young children and sero-positive adults 
according to Barlam and Kasper (2009:540). Clinical features of tuberculous meningitis 
include headache, fever, vomiting, depression, confusion, lethargy, meningism and 
occasional ocular cranial nerve involvement.  
 
2.3.5 Diagnosis 
 
Diagnosis of TB disease is made by performing a complete clinical assessment that 
includes a medical history, physical examination, chest X-ray and laboratory tests 
(Manda 2009:50).  
 
2.3.5.1 Medical history 
 
The NDOH (NDOH, 2013a) recommends that investigation for TB disease be carried 
out if 2 or more of the following symptoms are present: 
 
 Cough of any duration 
 Sputum production (with or without haemoptysis) 
 Fever   
 Drenching night sweats 
 Unexplained weight loss 
 Loss of appetite, malaise, tiredness 
 Shortness of breath, chest pains 
 New palpable lymphadenopathy 
 
In taking the medical history from the patient, questions should be targeted towards 
ascertaining the existence of the aforementioned symptoms. In addition, past history of 
TB exposure and disease as well as history of past TB treatment should be probed as 
resistant TB could occur if past treatment was erratic (FPD 2010b:63). Existence of 
other disease conditions like HIV infection, diabetes mellitus, renal disease, 
haematological disease, silicosis and ingestion of immunosuppressive drugs should 
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also be questioned as these could increase the chances of contracting TB disease 
(FPD 2012:61). 
 
2.3.5.2 Physical examination 
 
A thorough physical examination should be performed on the TB suspect as this could 
provide more details about the overall condition of the patient and other findings 
capable of affecting the management plans for the patient (FPD 2010b:61). 
 
Most signs are not specific for TB disease. They include wasting, elevated temperature, 
tachycardia and deviation of the trachea, bronchial breathing, crackles and dull 
percussion notes (FPD 2012:62). 
 
2.3.5.3 Investigations 
 
Direct microscopy of sputum for detecting the acid-fast bacilli using the Ziehl-Neelsen 
technique is the commonest method for detecting pulmonary TB. A positive smear is 
sufficient for the presumptive diagnosis of TB though definitive diagnosis requires 
culture. In HIV-negative individuals, the sensitivity of Ziehl-Neelsen staining for 
diagnosis of TB disease is about 80%. This drops to as low as 20% in HIV co-infected 
individuals who are often smear-negative even though they have TB disease (Peter & 
Theron 2011:404). Approximately one fourth of HIV-infected persons with pulmonary TB 
disease have false-negative results (CDC 2009:20). Smear-negative sputum exists 
because cavities are less common in individuals with HIV with the load of the organism 
higher in the tissue. It should therefore also be investigated where the constitutional 
clinical features are present and there is no response to broad spectrum antibiotics (De 
Kock, Odayar, Page-Shipp & Conradie 2013:8). Smear-negative sputum sent for culture 
could turn out to be positive as only 10-100 viable organisms are required for diagnosis 
of TB using culture compared to 5 000-50 000 required in detecting the bacilli using 
direct microscopy (Reid & Innes 2010:692). FPD further indicates that diagnosis of 
smear-negative TB is either made with a positive culture result or with suggestive x-ray 
findings together with a medical decision to start TB treatment. However, this diagnostic 
method could be challenging due to the likelihood that in more advanced 
immunosuppression, chest radiography becomes more atypical.  
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Other diagnostic technologies available for TB detection in addition to the commonly 
available ZN staining and microscopy are indicated in table 2.5. The turn-around time 
for the Integrated Nucleic Acid Amplification Tests (see table 2.5), also known as 
GeneXpert is approximately 90 minutes long, making it the fastest way to diagnose TB 
disease using sputum. The sensitivity is also more than Ziehl-Neelson or Auramine test. 
In 2013, the NDOH rolled out GeneXpert to several public health facilities as the 
preferred method for diagnosing TB. GeneXpert is able to detect the presence or 
absence of both Mycobacterium tuberculosis complex DNA and rifampicin drug 
resistance (Peter & Theron 2011:404).  
 
The Xpert MTB/RIF refers to a cartridge-based system that employs an automated real-
time nucleic acid amplification technology for rapid and simultaneous detection of 
Mycobacterium tuberculosis and resistance to rifampicin (WHO 2011d:6). Also referred 
to as Gene Xpert, this test has been rolled out in select health facilities in South Africa 
and 76 other countries as at the end of 2012 (WHO 2013b). A recent demonstration 
study in 6648 participants found the sensitivity of a single GeneXpert assay for TB 
diagnosis to be 97% in smear-positive patients and 76.9% in smear negative TB cases 
with an overall specificity of 99% (Peter & Theron 2011:404).  
 
Advantages of the test includes quicker turn-around time of 90-120 minutes for TB 
diagnosis and detection of rifampicin resistant TB when compared with AFB that has a 
turn-around time of 2-3 days and sputum culture that may takes up to 60 days to 
diagnose resistant TB. The test can also be performed in any laboratory where smear 
microscopy can be performed and does not require biosafety cabinets or highly skilled 
technicians (Conradie 2011:428). Conradie further indicates that the Xpert system is 
less specific than Hain test, a form of Line Probe Assay (LPA) and confirmation of MDR-
TB by culture is still required. 
 
The automated liquid culture systems are available in most South African laboratories 
and have largely replaced the traditional solid culture methods. Peter and Theron 
(2011:406) further indicate that though it offers better sensitivity and speed than the 
solid culture test, it is expensive and requires excellent laboratory infrastructure in order 
to maintain good quality control. The Microscopic-Observation Drug Susceptibility 
(MODS) provides a cheaper alternative to culture systems. However, it is labour-
 
41 
intensive and suitable for research-limited settings with cheaper labour. It requires about 
7 days for TB diagnosis. 
 
The Rapid Speciation Line Probe Assay (LPA) is used for rapid genotypic rifampicin and 
isoniazid drug susceptibility testing. It has high sensitivity for rifampicin resistance. In 
South Africa, it is routinely available for MDR-TB suspects. Another point of care 
method for TB diagnosis is the lipoarabinomannan (LAM) rapid test. The test is 
designed for TB diagnosis in hospitalised HIV and TB co-infected patients with 
advanced immunosuppression using the urine sample. This method is not yet publicly 
available in South Africa even though it is cheaper than the GeneXpert.    
 
Table 2.5 Diagnostic technologies for tuberculosis 
 
TECHNOLOGY TURN AROUND SENSITIVITY GAIN 
Ziel Neelson (ZN) 2-3 days  
   
Solid culture 30-60 days Baseline 
   
Liquid culture 15-30 days +10% 
   
Rapid speciation  
Line Probe Assay 
 
2-4 days 
Compared to LJ 
Currently smear positive only 
   
Integrated Nucleic Acid 
Amplification Tests 
Gene Xpert MTB/RIF 
 
 
90 minutes 
 
 
+40% compared to ZN 
   
The Microscopic – 
Observation Drug  - 
Susceptibility  (MODS) 
 
7 days 
 
+14% compared to LJ 
   
T-cell based assays 
(Interferon – y-based assays) 
16-24days 
Hours if not batch run 
Overall sensitivity gain 
Unknown 
   
LED-based fluorescent 
microscopy 
 
1-2 days 
 
+10% compared to ZN 
   
TB Antigen Detection 
(Lipoarabino mannan- LAM 
Assay) 
3-4 hours 
Overall sensitivity gain 
Unknown; 52% sensitivity in 
HIV positive patients, 
specificity 89% 
 
(Naidoo et al 2010:3) 
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For patients with clinical features suggestive of extra pulmonary TB, needle aspiration 
or tissue biopsy of skin lesions, lymph nodes, pleural or pericardial fluid should be 
performed for histopathological examinations (CDC 2009:22). Furthermore, myco-
bacterial blood cultures might be useful for patients with features of disseminated 
disease or worsening immunodeficiency. Lumbar puncture for analysis of the 
cerebrospinal fluid (CSF) is used for diagnosing TB meningitis. There is a 
predominance of lymphocytes with rise in proteins and fall in CSF glucose levels. 
Enhanced CT brain may show hydrocephalus, brisk meningeal enhancement or 
intracranial tuberculoma in patients with TB meningitis (Allen, Lueck & Dennis 
2010:1208). 
 
2.3.6 Treatment of tuberculosis in adults 
 
TB disease needs to be treated with multiple drugs to avoid developing resistance. 
Resistance refers to clinical failure to respond to a prescribed treatment when any strain 
of the offending organism is unaffected by the medications. The use of more than one 
drug with different modes of action ensures complete clearance of the offending 
organism from the body. Drug resistant TB refers to any strain of Mycobacterium 
tuberculosis that is unaffected by one or more antibacterial drugs. This is purely a 
laboratory diagnosis (De Kock et al 2013:35). The resistant strain TB results in clinical 
failure to respond to the first-line anti-TB treatment. However, not all failure to respond 
to TB treatment implies that the TB strain is drug resistant. In some cases, failure to 
respond to anti-TB therapy is due to poor adherence, treatment default or direct 
infection with the resistant strain of the offending organism. These factors could, in turn, 
lead to development of resistant TB at a later stage. 
 
South Africa was the first country to produce the  four-drug fixed drug combinations 
(FDC) formulation recommended by the WHO for the treatment of TB disease and also 
became the first country to implement a fully FDC-based treatment regimen (FDP 
2012:93). The FDC implies that several drugs are combined to form one single tablet. In 
South Africa, the combinations used include RHZE, RH (150, 75) and RH (300,150). 
FDC simplifies treatment, minimises prescription errors and simplifies the management 
of drug supply (Blomberg as cited in FDP 2012:91). Adherence to the medications 
among TB patients is also enhanced by the use of FDC as pill count is reduced and 
patients cannot be selective in the choice of drugs to ingest. 
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For ease of management, TB patients are classified into new or retreatment patients. 
New patient is defined as a patient who has never had treatment for TB or who has 
taken anti-tuberculosis drugs for less than 4 weeks while retreatment refers to a patient 
who has taken TB treatment for 4 weeks or more in the past and either relapsed, 
defaulted or had treatment failure (The Aurum Institute 2012a:31). Figure 2.2 illustrates 
the FDC regimen for the treatment of new TB cases for adults also referred to as 
Regimen 1. The pre-treatment body weight, intensive phase and continuation phase 
treatment schedule is illustrated in the table, based on different weight bands.  
 
The weight-based dosing for management of adult patients who have been previously 
treated for TB is illustrated in table 2.6. As indicated, a combination of Rifampicin, 
Isoniazid, Pyrazinamide and Ethambutol in addition to daily injection with Streptomycin 
should be administered to patients for the first two months according to the pre-
treatment body weight. The drugs will be continued in the next one month aside 
Streptomycin after which Rifampicin, Isoniazid and Ethambutol are used for another five 
months. Streptomycin should however not be administered to pregnant patients and 
elderly patients aged over 65 years. 
 
 
 
Figure 2.2  Adult Regimen (Regimen 1): New cases for adults 
(De Cock et al 2013:39) 
0
0.5
1
1.5
2
2.5
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4
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5
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>70kg
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Table 2.6 Adult Regimen (Regimen 2): Previously treated 
 
Pre-
treatment 
body 
weight 
Intensive phase 
(7 days a week for 2 months) 
Intensive 
phase 
(7 days a 
week for 1 
month) 
Continuation phase 
(7 days a week for 5 months) 
RHZE 
150,75,400,275 
Streptomycin 
(g) 
RHZE 150, 
75, 400, 
275 
RH 150, 75 E 400 
RH 300, 
150 
30-37 2 0.5 2 2 2  
38-54 3 0.75 3 3 2  
55-70 4 1.0 4  3 2 
>70 5 1.0 5  3 2 
 
(The Aurum Institute: A prescribers guide for managing TB & HIV) 
 
Where rapid tests like LPA or Xpert MTB/RIF are available, all previously treated 
patients diagnosed with sensitive TB must be started on Regimen 1, instead of 
Regimen 2 while those confirmed as rifampicin resistant must be started on MDR-TB 
treatment. This implies that Regimen 2 will be phased out over time as scale-up of rapid 
tests for MDR-TB is implemented. 
 
2.3.7 Drug resistant tuberculosis 
 
Drug resistant TB refers to any strain of Mycobacterium tuberculosis that is unaffected 
by one or more antibacterial drugs and is purely a laboratory diagnosis (De Kock et al 
2013:35). Drug-resistant TB results in clinical failure to respond to the first-line anti-TB 
treatment. However, not all failure to respond to TB treatment implies that the TB strain 
is drug resistant. In some cases, failure to respond to anti-TB therapy is due to poor 
adherence, treatment default or direct infection with the resistant strain of the offending 
organism.  
 
In 2010, the WHO endorsed the use Xpert MTB/RIF (Gene Xpert) for the simultaneous 
testing for pulmonary TB and Rifampicin resistance (WHO 2013c:59). The GeneXpert 
test is also used routinely in most health facilities in South Africa as the first-line 
investigation to diagnose TB disease and it also detects resistance to Rifampicin which 
is one of the first-line anti-TB drugs. This could happen in either sputum smear positive 
or smear negative individuals. 
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Following detection of Rifampicin resistance, another sputum sample is sent for 
microscopy, culture and phenotypic drug susceptibility testing (DST) for confirmation. 
While awaiting the outcome of the DST, the patient is registered, notified and 
commenced on Multi-drug resistant (MDR-TB) treatment.  
 
The outcome of the DST testing determines the next line of management. Diagnosis of 
MDR-TB is confirmed if resistance to Rifampicin and Isoniazid is detected in which case 
the management instituted earlier is continued. However, if the result indicates 
resistance to Rifampicin and susceptibility to Isoniazid, the patient is managed as mono-
resistant TB in which case Isoniazid is added to the MDR-TB treatment. MDR-TB 
treatment is discontinued and substituted with the first-line anti-TB regimen outlined in 
table 2.7 if isoniazid mono resistance is detected by the DST.  
 
Table 2.7   Intensive phase treatment of MDR-TB for adults and children >8 years 
 
Patients weight Drug Dosage 
<33kg 
Kanamycin 15-20 mg/kg 
Moxifloxacin 400 mg (children: 7.5-10 mg/kg) 
Ethionamide 15-20 mg/kg 
Terizidone 15-20 mg/kg 
Pyrazinamide 30-40 mg/kg 
33-50kg 
Kanamycin 500-750 mg 
Moxifloxacin 400 mg 
Ethionamide 500 mg 
Terizidone 750 mg 
Pyrazinamide 1000-1750 mg 
51-70kg 
Kanamycin 1000 mg 
Moxifloxacin 400 mg 
Ethionamide 750 mg 
Terizidone 750 mg 
Pyrazinamide 1750-2000 mg 
>70kg 
Kanamycin 1000 mg 
Moxifloxacin 400 mg 
Ethionamide 750-1000 mg 
Terizidone 750-1000 mg 
Pyrazinamide 2000-2500 mg 
 
(De Kock et al 2013:54) 
 
The duration of the intensive phase in MDR-TB treatment is determined by adding 4 
months to the date of collection of the first sputum that turned TB culture negative while 
the duration the continuation phase will be determined by adding 18 months to the date 
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of TB culture conversion (De Kock et al 2013:54). Tables 2.7 and 2.8 indicate the MDR-
TB treatment regimen for both the intensive and the continuation phases in adults and 
children older than 8 years. The actual dosing of the medications is determined by the 
weight of the affected patient. In addition to the standardised regimen, pyridoxine is to 
be given to patients on terizidone at a daily dose of 150-200 mg. 
 
Table 2.8 Continuation phase treatment of MDR-TB for adults and children >8 
years 
 
Patients weight Drug Dosage 
<33kg 
Moxifloxacin 400 mg 
Ethionamide 15-20 mg/kg 
Terizidone 15-20 mg/kg 
Pyrazinamide 30-40 mg/kg 
33-50kg 
Moxifloxacin 400 mg 
Ethionamide 500 mg 
Terizidone 750 mg 
Pyrazinamide 1000-1750 mg 
51-70kg 
Moxifloxacin 400 mg 
Ethionamide 750 mg 
Terizidone 750 mg 
Pyrazinamide 1750-2000 mg 
>70kg 
Moxifloxacin 400 mg 
Ethionamide 750-1000 mg 
Terizidone 750-1000 mg 
Pyrazinamide 2000-2500 mg 
 
(De Kock et al 2013:55) 
 
2.4 TUBERCULOSIS AND HIV CO-INFECTION 
 
HIV is the strongest risk factor yet recognised in the reactivation of latent or new 
Mycobacterium tuberculosis infection to active TB disease (WHO 2011a:1). The 
increased risk of active TB occurs soon after HIV sero-conversion and doubles by the 
end of the first year of HIV infection (Granich, Akolo, Gunneberg, Getahun, Williams & 
Williams 2010:S215). 
 
The lifetime risk of an infected but immune-competent individual developing active TB 
disease is around 10% with the highest risk in the first two years following infection  
(WHO as cited in FPD 2010b:14). The risk increases to around 10% per year in an 
individual infected with HIV (Wilson, Cotton, Bekker, Meyers, Venter & Maartens 
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2008:36).  Wilson et al (2008:36) further indicate that while disease caused by the 
relatively non-virulent non-tuberculous mycobacteria such as Mycobacterium avium 
complex tends to affect those with very low blood CD4 lymphocyte counts, the risk of 
TB disease increases after HIV seroconversion and is elevated across the full spectrum 
of immunodeficiency, increasing steeply as the CD4 cell count declines.  
 
A study on HIV-infected South African adults found that whereas ART alone decreased 
the adjusted risk of TB by 64%, the incidence of the disease remained high at 4.6 cases 
per 100 person years (Golub et al 2009:5). This reflects a rate 10 times higher than the 
overall incidence of TB in the South African population and 1000-fold that in the United 
States. 
 
In addition to high rates of reactivation TB, HIV-infected persons have also been found 
to have a heightened susceptibility to new exogenous infection and rapidly progressive 
primary disease. Genetic fingerprinting studies have shown that high TB recurrence 
rates are fuelled by a high rate of exogenous reinfection (Wilson et al, 2008:36). The 
HIV positive individuals that are co-infected with TB are about 21-24 times more likely to 
develop TB disease compared with those who are HIV negative (WHO, 2011b:61). This 
is because HIV weakens the immune system of the affected individual and may render 
it completely defenceless against the invading organism. A study carried out among 
miners in four mines located in Gauteng, South Africa, revealed that the HIV-positive 
miners were significantly more likely to develop TB disease than their counterparts who 
were HIV-negative (Sonnenberg, Glynn, Fielding, Murray, Godfrey-Fausseth & Shearer 
2004:153). The incidence of TB was found to have doubled within the first year and 
increased four-fold after 2 years among miners that participated in the particular study. 
 
It is estimated that without intensified intervention, 2 million PLHIV will die of TB 
between 2011 and 2015 (WHO 2011c:2). The African region accounted for about 82% 
of the new TB cases among PLHIV in 2010. This translates to an estimated 900,000 
people representing 39% of the global 2.3 million HIV-positive individuals diagnosed of 
TB disease the same year according to the WHO (2011c:2). 
 
About 65% of TB patients are co-infected with HIV compared to the global average of 
20% and about 16% for the region of Americas (WHO 2013c:70). FPD (2010b:127) 
indicate that TB is the commonest cause of morbidity and mortality among HIV-infected 
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population in South Africa and has been shown to accelerate HIV disease progression. 
This explains the recommendation that measures aimed at preventing TB among the 
HIV-infected should be offered in the package of care for people living with HIV (NDOH 
2010b:4).  
 
2.4.1 Clinical features of TB in HIV co-infected individuals 
 
Several clinical features of TB are found in individuals co-infected with HIV. The clinical 
features of TB in HIV-infected individuals with high CD4 counts are similar to those of 
non-HIV-infected individuals with active TB disease with progression of deficient 
immune state associated with an increasing frequency of cutaneous abnormal immune 
response to purified protein derivative and an increased risk of extra pulmonary forms of 
TB disease (Wilson et al 2008:36).  
 
The signs and symptoms include cough, profuse night sweats, loss of appetite, pleuritic 
chest pain, haemoptysis, fever and weight loss (FPD 2010a:154). 
 
2.4.2 Diagnosis of TB in HIV-positive individuals 
 
2.4.2.1 Sputum smear microscopy 
 
The underlying immune status of the HIV-infected TB patient affects the sensitivity 
sputum smear microscopy result. This is in addition to other factors, such as poor 
quality of sputum, poor quality of laboratory service, and poor microscopy techniques 
(FPD 2010a:154). Sputum smear-negative TB is more commonly seen in HIV-infected 
individuals. Smears are negative in such individuals more often because cavities are 
less common as the organism load in tissues is higher than in individuals who are not 
infected with HIV (Peter & Theron 2011:404). In such situations, diagnosis is either 
made with a positive culture, gene Xpert test or with suggestive x-ray findings together 
with a medical decision to start TB treatment based on the clinical features. 
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2.4.2.2 Xpert MTB/RIF 
 
The Xpert MTB/RIF test has been found to be 76.9% sensitive in smear negative TB 
cases which abound in TB/HIV co-infected individuals (Peter & Theron 2011:404). In 
most health facilities in South Africa, this test has replaced sputum microscopy test for 
routine use in diagnosing TB in HIV co-infected individuals. 
 
2.4.2.3 Chest X-ray  
 
In HIV-infected individuals, the chest x-ray could be used in establishing the diagnosis 
of TB where only one sputum sample is positive for TB or two negative sputum smears 
are noted in a patient who continues to cough despite a full course of broad-spectrum 
antibiotic (FPD 2012:121). FPD indicates further that in the early stages of HIV disease, 
common x-ray findings may include cavitation, focal infiltrates in the upper chest and 
hilar regions, hilar adenopathy and pleural or pericardial effusions. The findings may 
also be atypical with pulmonary infiltrates noted throughout the lungs rather than 
cavities in the upper lobes of the lungs. The sensitivity and specificity of chest x-ray in 
the diagnosis of active TB disease is reduced in smear negative mostly HIV-positive 
individuals due to less pronounced cavities and is operator-dependent (Cleef, Kivihya-
Ndugga, Meme, Odihiambo & Klaster 2005:6). However, chest x-ray should not replace 
TB symptom screening as some chest x-ray findings are not specific to TB disease. The 
inconsistency in the reading and interpretation of x-ray among clinicians and radiologists 
further reduces the specificity of the x-ray in the diagnosis of active TB disease (FPD 
2012:121). The WHO (2013d:81) recommends the use of chest x-ray as a second 
screening method for individuals with symptoms suggestive of TB after either sputum 
smear microscopy or rapid molecular test such as Xpert MTB/RIF. However, individuals 
with abnormal Chest x-rays suggestive of TB when done prior to the diagnostic tests 
should be further evaluated.  
 
2.4.2.4  Sputum culture 
 
Sputum culture testing is the gold standard for TB diagnosis in both HIV-infected and 
non-HIV infected individuals as HIV has no effect on the test sensitivity and specificity 
(De Kock et al 2013:25). This test could be done on any clinical specimen and has high 
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sensitivity with the added capability of detecting TB cases before they become 
infectious. Due to the fact that culture is more expensive and requires 2-6 weeks wait 
for the result, it is not considered as an initial diagnostic test except in settings where 
resources permit and the health system has sufficient capacity to ensure that patients 
are followed after the culture results are available (WHO 2013d:81). The long wait for 
the result could increase the morbidity and mortality associated with active TB disease. 
The culture may then be used in parallel with or after testing with the Xpert MTB/RIF or 
sputum-smear microscopy. FPD (2010a:155) indicates that this test is not necessary, 
however, if sputum microscopy has already tested positive but remains a useful tool for 
excluding active TB disease in an HIV individual prior to considering IPT. This was 
deemed important for the study as exclusion of active TB disease is recommended prior 
to commencing IPT on the patient.  
 
2.4.3 Diagnosis of extra-pulmonary TB 
 
This form of TB disease is more common in HIV-infected individuals, particularly those 
with low CD4 count. The lymph nodes, pleural cavity and the pericardium are the usual 
sites of HIV-associated extra-pulmonary TB (FPD 2012:121). Needle aspirations, 
inspection of biopsied lymph nodes for macroscopic caseation, cultures and direct 
smears for AFB are some of the methods of establishing diagnosis of extra-pulmonary 
TB disease. Blood cultures for Mycobacterium tuberculosis could also be used. 
 
2.5 TB PREVENTIVE TREATMENT 
 
2.5.1 Introduction 
 
The WHO (2011a:1) provides clear recommendations about interventions needed to 
prevent, diagnose and treat TB in PLHIV. The recommendations are collectively 
referred to as collaborative TB/HIV activities, and include HIV testing of TB patients, 
provision of anti-retroviral therapy (ART) and CPT to TB patients living with HIV, HIV 
preventive services for TB patients, intensified TB case-finding among people living with 
HIV, isoniazid preventive therapy (IPT) for PLHIV who do not have active TB and 
infection control in healthcare and assembly settings. Active TB screening offers the 
opportunity to provide preventive therapy for those who do not have symptoms and 
signs of TB. 
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Isoniazid Preventive Therapy (IPT) refers to the intake of isoniazid by individuals that 
have latent infection with Mycobacterium tuberculosis in order to prevent the 
progression to active TB disease.  The WHO (2011a:6) recommends that adults and 
adolescents living with HIV who have an unknown or positive Tuberculin Skin Test 
(TST) status and who are unlikely to have active TB should receive at least six months 
of IPT as part of a comprehensive package of HIV care irrespective of the degree of 
immunosuppression, pregnancy status, whether the patient is on ART or have 
previously been treated for TB. In practice however, TST which identifies people with 
latent TB infection often constitutes an impediment for the provision of IPT. This is 
largely due to shortage of personnel to carry out the test and occasional reluctance of 
patients to return back to the clinic within 48 hours for the interpretation in addition to 
possible false positive or negative results. The NDOH (2013a:14) recommends a TST 
prior to commencing patients with no sign or symptom of TB on IPT. However, if no TST 
is done, IPT should be continued for six months but efforts should be made to perform 
TST as soon as possible after commencement on IPT.  
 
Performing TST is important as it guides in determining the length of treatment.  
However, Rangaka, Wilkinson, Boulle, Glynn, Fielding, Cutsem, Wilkinson, Goliath, 
Mathee, Goemaere and Maartens (2014:7) revealed that the benefit of IPT on patients 
on ART was found to be greater in individuals who had negative TST compared to 
those who were positive and recommended IPT to all eligible patients receiving ART in 
moderate to high TB incidence areas irrespective of the TST results. According to the 
study, the finding that in HIV-positive patients with low CD4 count that reside in high 
prevalence areas tend to have more false negative TST results may have accounted for 
their finding. The outcome of this study differed from an earlier report by Wilkinson, Kon, 
Newton, Meintjes, Davidson, Pasvol and Wilkinson (2006:355) which found non-existent 
efficacy of IPT in TB-exposed individuals with negative TST results and concluded that 
TST may have been flawed in both sensitivity and specificity. IPT is however one of the 
interventions recommended by the WHO that reduce the morbidity and mortality from 
TB in PLHIV (WHO 2011b:1). 
 
2.5.2 Mechanism of action of Isoniazid (INH) 
 
INH is an artificial equivalent of pyridoxine that is made as a prodrug which when 
ingested is activated by a mycobacterial catalase-peroxidase (Howland & Mycek 
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2006:396). Once ingested, the drug is activated and inhibits the enzymes that are used 
for the synthesis of mycolic acid in the mycobacterial cell wall. 
 
Isoniazid exhibits bacteriostatic and highly potent bactericidal action against 
mycobacterium tuberculosis that causes TB disease (FPD 2010a:95).  
 
2.5.2.1 Pharmacokinetics of INH 
 
INH when taken orally is well absorbed though this could be impaired if the drug is 
taken with food or aluminium-containing antacid preparations (Howland & Mycek 
2006:397). The drug penetrates the host cells where it acts against TB bacilli growing 
within the intracellular space. The inactive metabolic products and unchanged INH are 
excreted by the kidneys in the urine (Rossiter 2012:320). 
 
2.5.2.2 Adverse effects of INH 
 
Neurotoxicity is a notable dose-related adverse effect of INH. It could manifest as 
peripheral neuropathy, seizures, psychosis and optic neuritis according to Rossiter 
(2012:320). Peripheral neuropathy manifesting as paraesthesia is the most common 
adverse effect (Howland & Mycek 2006:397). This is thought to be due to the inhibitory 
effect of INH on the metabolites of pyridoxine and explains why pyridoxine is routinely 
prescribed for patients on INH for prevention and treatment of peripheral neuropathy 
(Lobue & Menzies 2010:609). 
 
Hepatotoxicity in the form of drug induced hepatitis could occur with intake of isoniazid. 
This is caused by monoacetylhydrazine which is a metabolic product of INH (Howland & 
Mycek 2006:397). Regular alcohol consumption and age >35 years old are factors that 
are associated with development of INH-associated hepatotoxicity (Lobue & Menzies 
2010:609). 
 
Other possible adverse effects of INH include anaemia, hypersensitivity reactions, 
thrombocytopenia, neutropenia and hypersensitivity reactions manifesting as fever, 
chills and rarely arthritis (Rossiter 2012:320). 
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2.5.2.3 Drug interactions 
 
INH interacts with the metabolism of several drugs. It can potentiate the adverse effects 
of Phenytoin by inhibiting the metabolism of the drug (Rossiter 2012:230). The adverse 
effects include nystagmus and ataxia. INH reduces the serum concentrations of 
Cyclosporine, ketoconazole and oral contraceptives and increases levels of 
pentamidine, ethosuximide, theophylline, diazepam and carbamazepine (Turner 
2010:272).  
 
2.5.3  Possible mechanisms of IPT efficacy 
 
The effect of IPT on the incidence of TB may therefore have been because of treatment 
of early, subclinical or latent Mycobacterium tuberculosis infection (Zar, Cotton, Strauss, 
Karpalis, Hussey, Schaaf & Rabie 2006:5). Zar et al (2006:5) further indicate that IPT 
may have provided primary or secondary prophylaxis against infection. Rangaka et al 
(2014:7) reported recently that treatment for latent TB with INH alters the body’s 
immune response to tuberculosis by releasing mycobacterial antigens. Increased 
numbers of Mycobacterium tuberculosis-specific gamma interferon-producing T-cells 
was noted after commencing patients on INH (Wilkinson et al 2006:357). INH is a potent 
anti-TB drug that works by inhibiting mycolic acid synthesis in the bacterial wall and is 
found to be bactericidal after 24 hours of ingestion (FPD 2010a:95).   
 
2.5.4 Advantages of IPT  
 
In a study in Cape Town, isoniazid prophylaxis was found to have significantly reduced 
mortality in children with HIV who were living in areas with high prevalence of TB and 
the incidence of confirmed or probable TB cases by intention to treat analysis was found 
to be lower in the isoniazid group than in the placebo group (Zar et al 2006:5).  Thus, 
the protective effect of isoniazid on the incidence of TB occurred in all categories of 
severity of clinical disease in children aged more than one year and in both dose 
regimen. Ayieko, Abuogi, Simchowitz, Bukusi, Smith and Reingold (2014:9) found that 
IPT reduces the risk of TB by 59% among children ≤15 years of age and thus confers 
protective effect against TB among HIV-negative children. Zar et al (2006:5) 
nevertheless acknowledged that their study lacked sufficient data required to make a 
definite conclusion on the efficacy of INH in preventing TB in HIV-positive children. 
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Some level of protection against TB and a reduction in mortality among the TST-positive 
subjects studied were noted after six months intake of isoniazid (Hawken, Mene, Elliot, 
Chakaya, Moris, Githui, Juma, Odhiambo, Thiong’o, Kumari, Ngugi, Bwayo, Gills, 
Plummer, Porter, Nunn & McAdam 1997:881). The study findings were not statistically 
significant when compared to the group of study population that did not receive 
isoniazid. Golub, Pronyk, Mohapi, Thsabangu, Moshabela, Struthers, Gray, McIntyre, 
Chaisson and Martinson (2009:5) also indicate that the combined effect of both IPT and 
ART was associated with 89% decrease in the adjusted risk for TB with a crude 
incidence of 1.1 cases per 100 person years following a study they conducted. This 
implies that in conjunction with ART initiation, widespread use of IPT has the potential to 
lead to further reductions in TB incidence among the HIV-infected adults in high TB 
burden settings. Also, 12 months of IPT reduced the incidence of tuberculosis in 
patients receiving ART by 37% (Rangaka et al 2014:6). A retrospective study of HIV 
positive patients in Ethiopia revealed that initiating IPT after starting ART resulted in 
92% protective effect from active TB disease (Yirdew, Jerene, Gashu, Edginton, Kumar, 
Letamo, Feleke, Teklu, Zewdu, Weiss & Ruff, 2014:4). However, this group of patients 
was considered low risk prior to the study as TB disease incidence after their initiation 
on ART but prior to IPT was 0.2 per 100 person years. 
 
In the public health perspective, INH prophylaxis is cost effective, extends life 
expectancy, reduces the incidence of TB and promotes savings in medical and social 
costs in adults with HIV, especially those who are tuberculin skin test positive and INH 
has also been shown to inhibit the development of malarial parasite (Zar et al 2006:5). 
 
Concerns about implementing IPT programmatically include difficulties in detecting 
active TB, selection for INH resistance and toxicity and achieving optimal adherence to 
IPT. Good adherence to IPT appears to be a historical problem with a reported 54% of 
patients receiving the recommended 6 months of IPT in a study by Golub et al (2009:5).  
 
Active TB can be excluded using relatively simple screening measures and there is little 
evidence that IPT results in the emergence of drug resistance (Golub, Saraceni, 
Cavalcante, Pachebo, Moulton, King, Efron, Moore, Chaisson & Durovni 2007:7). A TB 
preventive therapy is an effective intervention for HIV-infected individuals and all people 
living with HIV should be screened for active TB and assessed for their eligibility to be 
enrolled on ART (NDOH 2013a:14). While those who are eligible for ART should be 
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started on ART, all PLHIV in whom active TB have been excluded should be started on 
IPT unless alcohol abuse, adherence to IPT when instituted or possible side effects are 
of concern in which case counselling should precede IPT according to NDOH.  
 
There has been concerns that intake of IPT could lead to INH-resistant TB (Balcells et 
al 2006:744). This is one of the reasons adduced for poor uptake of IPT for the 
prevention of progression to active TB disease in interactions between the researcher 
and some clinicians. However, the main cause of resistance to anti-tuberculosis 
medication has been found to be inadequate treatment of active TB disease (Balcells et 
al 2006:760). Isoniazid resistant-TB was not significantly attributable to previous IPT 
intake according to Balcells et al (2006:760). TB disease among mostly HIV-infected 
people who took IPT had treatment outcomes and similar prevalence of isoniazid 
resistance when compared with findings from similar setting among those that did not 
take IPT (Van Halsema, Fielding, Chihota, Russel, Lewis, Churchyard & Grant 
2010:1054). 
 
Routine diagnosis of isoniazid mono-resistance TB by DST in isolation is not 
programmatically recommended by the WHO which rather, recommends that DST 
should be performed after the conventional testing method has detected resistant TB 
(WHO 2010b:88). In South Africa, DST is required to make a definitive diagnosis of 
MDR-TB only after the Xpert MTB/RIF has already detected Rifampicin-resistance TB in 
which case, IPT cannot be implicated as the sole cause of the resistant TB (NDOH, 
2011c:36). Routine six to nine months of treatment with regimen of medications used 
during the intensive phase (Fixed dose combination of Isoniazid, Rifampicin, 
Pyrazinamide and Ethambutol) is however recommended for Isoniazid mono-resistant 
TB (De Cock et al 2013:52).  
 
Notwithstanding the absence of definitive evidence from randomised controlled trials on 
optimal duration of IPT in HIV-infected patients, data from several observational studies 
demonstrate that IPT is both cost effective and beneficial through combating low 
bacillary load latent TB which serves as a reservoir for recurrent disease (Naidoo, 
Naidoo, Padayatchi & Karim 2010:3). Naidoo et al (2010:3) also found that the 
concurrent administration of ART and IPT has demonstrated a TB risk reduction of 76-
89% in observational studies from both SA and Brazil though the protection offered by 
IPT to those infected with HIV may depend on a number of factors. These factors 
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include degree of immune suppression of the individual, duration of IPT, adherence to 
and potency of the regimen as well as general risk of reinfection in that setting.  
 
2.5.5 Duration of IPT 
 
Prior to commencing a patient on IPT, both the WHO (2011a:5) and NDOH (2013a:14) 
recommend that active TB disease should be excluded prior to commencing IPT. The 
screening entails asking the patients about the existence of symptoms suggestive of 
active TB disease. The questions are outlined in the screening tool developed by NDOH 
(see Annexure F) and include existence of cough, loss of weight, night sweat or fever. It 
is recommended that where any of the symptoms exist, further screening for active TB 
disease using Xpert MTB/RIF, chest x-ray or sputum culture where indicated should be 
performed. See Annexure G for the recommended screening algorithm for TB 
prophylactic therapy. 
 
While more studies are required to establish optimal duration of IPT in HIV-infected 
patients in high burden TB settings, current data suggest benefits from IPT when used 
for a period of nine months post-TB therapy (Naidoo et al 2010:3). The recommended 
dose is 5mg/kg to a maximum of 300mg daily with pyridoxine administered alongside 
Isoniazid to suppress the side effects (NDOH 2013a). Table 2.9 indicates the NDOH 
recommendations regarding the duration of IPT. Where no TST is done and the patient 
is not on ART with a CD4 cell count of >350, IPT should be administered for 6 months 
with efforts intensified towards performing TST as soon as possible after starting IPT.  
The same duration of treatment is recommended for patients on ART. However, if the 
TST done is negative, IPT should be continued for 12 months for those on ART while 
those not yet on ART with CD4 more than 350 should receive IPT for 6 months. At the 
same time, where TST done on a patient that qualifies for IPT is positive and the patient 
is not yet on ART with CD4 count more than 350 or on ART, IPT should be taken for at 
least 36 months. Table 2.9 illustrates a summary of the NDOH recommendations for the 
institution of IPT. In the USA, INH is recommended to be taken for 9 months though 
some public health programmes recommend 6 months, based on cost-effectiveness 
(Lobue & Menzies 2010:608). 
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Table 2.9 Summary of NDOH recommendations for IPT administration  
 
 Pre-ART On ART 
TST not done IPT for 6 months IPT for 6 months 
TST negative IPT for 6 months IPT for 12 months 
TST positive IPT for at least 36 months IPT for at least 36 months 
 
(NDOH 2013a:14) 
 
2.6 CONCLUSION  
 
This chapter discussed the literature review undertaken for the study. The literature 
covered the epidemiology, pathogenesis, transmission, clinical features, current 
investigation modalities and treatment of TB, HIV, and TB co-existing with HIV. The 
possible mechanisms of IPT efficacy, advantages and recommended duration of IPT 
were also discussed. Although the researcher found no literature or data on the 
incidence of TB disease after intake of IPT in iLembe district and poor adherence to 
IPT, the literature review guided the researcher in terms of developing the 
questionnaire. 
 
Chapter 3 describes the research design and methodology. 
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CHAPTER 3 
 
Research design and methodology  
 
 
3.1 INTRODUCTION 
 
This chapter discusses the research design and methodology, including the population, 
sampling and sample, data collection and analysis, data-collection instrument, and 
ethical considerations.  
 
3.2  RESEARCH DESIGN 
 
A research design refers to the overall structure or plan for the research (Bowling 
2009:158). Grove et al (2013:195) define a research design as a blueprint for 
conducting research which is the entire strategy for the study. The researcher 
conducted quantitative, non-experimental, descriptive, retrospective cohort study to 
ascertain the incidence of TB amongst adult HIV-positive clients who received IPT at 
Isithebe Clinic, KwaZulu-Natal, South Africa.  
 
Protection from TB disease after 6 months duration of IPT declined after 18 months of 
commencing the therapy (Johnson, Okwera, Hom, Mayanja, Kityo, Nsubuga, Nakibali, 
Loughlin, Yun, Mugyeni, Vernon, Mugerwa, Ellner & Whalen 2001:2144). Protection 
from TB disease has been found to last up to 30 months (Aїt-Khaled, Alacron, Bissell, 
Boillot, Caminero, Chiang, Clevenbergh, Dlodlo, Enarson, Enarson, Ferroussier, 
Fujiwara, Harries, Heldal, Hinderaker, Kim, Lienhardt, Rieder, Rusen, Trébucq, Van 
Deun & Wilson 2009:930). Given these findings, the researcher chose the duration used 
for the study to allow for between 15 and 30 months protective action of IPT prior to 
data collection and analysis. Thus data were collected from clinic records of patients 
who were commenced on IPT between July, 2010 and November, 2011.  
 
A non-experimental design was appropriate because there was no manipulation of the 
independent variables, no intervention took place and the setting was not controlled 
(Brink, Van der Walt & Van Rensburg 2012:112). A descriptive study refers to a simple 
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description of the health status of a community based on routinely available data or on 
data obtained in special surveys thus the study was descriptive in nature (Bonita et al 
2006:40).  
 
In studies with a retrospective design like this one, a phenomenon existing in the 
present is linked to a phenomenon that occurred in the past (Polit & Beck 2012:224). 
Retrospectively, data for this study were collected from records of HIV-positive patients, 
who accessed IPT from Isithebe Clinic between July, 2010 and November, 2011. Thus 
whether TB occurred among the population under study was linked to their intake of IPT 
within the designated period. Both the proposed cause, which is intake of IPT, and the 
proposed effect, which in this study refers to occurrence of TB disease in the sample 
population, had already occurred and the variables were not manipulated (Grove et al 
2013:219). The choice of a cohort study was because the records were for a group of 
people who shared certain characteristics, which in this case were HIV-positive clients 
commenced on IPT that were followed-up after 6 months of treatment (Joubert & Ehrlich 
2007:79). 
 
3.3 RESEARCH SETTING 
 
The research setting refers to the location where a study is conducted (Grove et al 
2013:373). A natural (field) setting where the environment was uncontrolled was chosen 
for the study. The research was conducted at Isithebe Clinic that falls under the 
Mandeni Municipality. Mandeni is a municipality in iLembe Health District of KwaZulu-
Natal Province in South Africa.  
 
Isithebe is an industrial area adjacent to formal urban settlement in Mandeni. It is 
therefore classified as an urban area (Statistics South Africa 2004:16). Located in the 
northern part of the district (see figure 3.1), the clinic provides the full complement of 
HIV/AIDS/TB management to the inhabitants of Mandeni Municipality and others who 
attend the clinic. 
 
Services rendered include Provider-initiated Counselling and Testing (PICT); HIV 
Counselling and Testing (HCT); wellness clinic; Post Exposure Prophylaxis (PEP); Adult 
and Paediatric antiretroviral treatment; Prevention of Mother-to-child transmission 
(PMTCT) services; adherence support, assessment and monitoring; TB/HIV care; family 
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planning and other related services. The clinic attendees are largely semi-skilled and 
unskilled workers of the Isithebe Industrial Area and their families. 
 
3.4 POPULATION 
 
Population refers to the entire aggregate of cases in which a researcher is interested. 
The accessible population refers to the cases that conform to the inclusion criteria and 
are available for the study, and the target population is the aggregate of cases to which 
the researcher would like to generalise the findings (Polit & Beck 2012:274). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1  Map of iLembe District showing health facilities located in the district 
(iLembe District Municipality 2014:30) 
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A total of 441 records were identified for the study according to the daily clinic 
attendance register that was available. From the 441, 104 clinic records of HIV-infected 
adult clients managed at Isithebe Clinic met the eligibility criteria for the study and were 
the sample. The criteria to be included in the study were evidence that the patient tested 
HIV positive, was more than 18 years old and commenced IPT at Isithebe Clinic. The 
cut-off enrolment month of November 2011 was chosen because the records of the 
patient for 15-30 months were followed to ascertain if they developed active TB disease 
after using IPT. The records of patients enrolled on IPT earlier than July 2010 was not 
used due to limitation in finances and time constraints.  
 
The number of records used was less than initially anticipated. This was due to the 
discovery during the data collection stage that many of the patients initially indicated as 
eligible for the study judging from the entries on the daily clinic register were screened 
for TB disease but were not eventually enrolled for IPT. Inadequate record keeping also 
made it difficult to access some of the records while some of the patients whose records 
initially met the eligibility criteria while the study was proposed no longer qualify for the 
study. This was because they were no longer accessing care at the facility.It was 
therefore difficult ascertaining whether they had active TB disease after intake of IPT. 
 
3.5 SAMPLING 
 
The study sample refers to the most basic unit of the population element about which 
data are collected (Polit & Beck 2012:275). Consecutive sampling was used for the 
study. The entire 104 patients’ records that met the inclusion criteria were used. 
According to the daily clinic register, 441 HIV-positive patients were enrolled on IPT 
within the period being studied. However, during the actual perusal of the identified 
folders, it was discovered that the majority of them were screened for TB disease but 
were not eventually commenced on IPT, thus only 104 were included in the study. 
 
3.5.1 Inclusion criteria 
 
The clinic records of patients that were used for the study met the following criteria: 
 
 Evidence that the patient tested positive for HIV. 
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 The patient was 18 years or older. The choice of 18 years is because of the legal 
requirement of securing consent from parents which could be difficult considering 
the design of the study. Thus the study was intended for adult population. 
 IPT was commenced from July, 2010 up to November, 2011. 
 The therapy was commenced at Isithebe Clinic. 
 
3.5.2 Exclusion criteria 
 
Clinic records were excluded from the study sample if: 
 
 They belonged to patients that were demised before commencement of the 
study. 
 The patients relocated from the area and were therefore transferred out of the 
facility for ongoing care at another facility at the time the data was collected.  
 Patients were lost to follow-up after initial screening. 
 IPT was discontinued due to adverse drug reaction. 
 The patients were mentally challenged adults commenced on IPT. 
 The records were incomplete with key data elements such as gender, age and 
IPT starting dates and screening to exclude active TB disease missing. 
 
3.6 RESEARCH TECHNIQUE 
 
3.6.1 Data-collection instrument development 
 
The development of the structured data-collection instrument took considerable time. 
The researcher developed the data-collection sheet after scrutinising literature relevant 
to the research topic, the problem and the objectives.  The data-collection instrument 
was then submitted to the Supervisor as well as a panel of experts and scientific 
committee in the Department of Health Studies at UNISA for scrutiny and comment, 
before the pilot study was conducted. 
 
Table 3.1 describes the variables recorded in the data-collection instrument and their 
categories of measurement. For the independent variables, age was continuous 
numerical, gender was nominal categorical; number of months on IPT was discrete 
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numerical while the TB screening method was numerical categorical. The dependent 
variables were also described.  
 
Table 3.1 Research variables and levels of measurement  
 
INDEPENDENT VARIABLES CATEGORY 
Age Continuous numerical 
Gender Nominal categorical 
Number of months on IPT Discrete numerical 
TB screening method Numerical categorical 
  
DEPENDENT VARIABLES CATEGORY 
CD4 count  Continuous numerical 
Viral load Continuous numerical 
Diagnosis of TB after IPT  Nominal categorical 
 
The data-collection instrument contained closed questions with numerical values 
attached to each of them to ensure standardised recording. The choice of closed 
questions was to ensure easier administration and analysis as well as save time (Polit & 
Beck 2012:298). 
 
The data-collection instrument was structured into three sections: 
 
 Section A: This section contained the biographical data, including the 
identification code, age (in years), gender and date of commencement on ART, if 
the patient was already taking ART. 
 Section B: Section B contained information relating to IPT, including pre-
screening for TB disease, method of TB screening used to exclude the disease 
prior to initiating on IPT, date of commencing IPT, number of months the patient 
received IPT, completion status, and number of months used to complete a 
course of IPT. The reason for stopping where indicated in addition to TB-disease 
status of the patient post-IPT was also included. 
 Section C: This section contained information pertaining to the last clinic visit of 
the patient prior to retrieval of the data from the clinic records. The last viral load 
and CD4 count of the patient, where retrievable, were the last part of this section. 
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3.6.2 Validity 
 
Validity refers to the extent to which an instrument measures what it is supposed to 
measure (Polit & Beck, 2013:336). It affirms the appropriateness of the data-collection 
instrument for the purpose for which it was designed (Grove et al 2013:394). The 
researcher extensively reviewed the literature and consulted with professional 
colleagues prior to designing the data-collection instrument. This enhanced the validity 
of the instrument.  
 
The use of medical records, which were extracted solely by the researcher, eliminated 
the possibility of influencing respondents’ responses thus enhancing the validity of the 
data-collection instrument. 
 
3.6.3 Reliability 
 
The reliability of an instrument means the consistency of the measures in the study 
(Grove et al 2013:389). Similar recordings of same clinic records were observed by 
different health workers when the data-collection instrument was evaluated during the 
pilot testing. This ensured the reliability of the instrument. The instrument was also 
submitted to the supervisor and a panel of research experts for review prior to 
commencement of the study. 
 
3.6.4 Pilot testing 
 
A pilot test of the data collection instrument was conducted at Isithebe Clinic prior to 
commencing data collection. The purpose of the pilot study was to evaluate the 
appropriateness and quality of the instrument. The 20 records used for the pilot study 
were conveniently selected. They were records of HIV-positive adults who received IPT 
prior to the period used for the main study. The pilot study did not lead to any further 
modification of the instrument or the study procedures and the results were not included 
in the analysis of the data. 
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3.7 ETHICAL CONSIDERATIONS 
 
Research ethics refers to the moral principles guiding research (Oxford Advanced 
Learner’s Dictionary 2010b:500). Since the first major international code of ethical 
principles in medical research referred to as the Declaration of Helsinki was produced 
by the World Medical Association in 1964, several ethical guidelines have been enacted 
by various countries, professional bodies and institutions (Barrett & Coleman 2005:556). 
 
In collecting data and other aspects of the study, the researcher maintained sound 
ethical principles in line with the ethical guidelines of the Department of Health Studies, 
UNISA and the KwaZulu-Natal Department of Health. 
 
Ethical approval for the study was obtained from the Research Ethics Committee of the 
Department of Health Studies, University of South Africa (see Annexure D). Permission 
for the study was also obtained from the KwaZulu-Natal Department of Health, iLembe 
District Department of Health and from the Management of Isithebe Clinic (see 
Annexures C and E). In order to maintain anonymity and confidentiality, the actual 
names of the participants whose records were used for the study were not indicated in 
the final entries entered onto the statistical software for analysis. In place of the actual 
names and file numbers, a code was used for identification. All the documents relating 
to the study were stored away from public access and will remain so for at least 5 years. 
The electronic data were password-protected to ensure denial of access to the data by 
unauthorised individuals. 
 
3.7.1 Protecting the rights of the institutions 
 
Permission to carry out the study was granted by the KwaZulu-Natal Department of 
Health. See Annexures D and E for the responses to the letters requesting permission 
to conduct the study and the authorisations letters from both the University and 
KwaZulu-Natal Department of Health.  
 
Authorities at the District Department of Health, iLembe, Sundumbili Community Health 
Centre and Isithebe Clinic were also assured in writing that sound ethical principles 
would be upheld by the researcher. This ensured that the confidentiality attached to 
patient information was not compromised during and after the study. Only the 
researcher abstracted the required information from the clinic records of the patients. 
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Data collection occurred during weekends when the patient traffic was lower than that 
experienced during the week. This ensured minimal disruption of clinic activities and 
enabled better concentration. The researcher also undertook to share the findings and 
recommendations of the study with the facility, district and provincial department of 
health. 
 
3.7.2 Right to self-determination 
 
Self-determination means that the research respondents should be treated as 
autonomous agents and allowed to voluntarily decide whether to participate in the study 
(Polit & Beck 2012:154). It also implies that the respondents have the right to withdraw 
from the study at any time of their choice without any penalty (Grove et al 2013:164). 
 
The study only involved the review of clinic records and therefore no patient was 
personally involved in this study.  
 
3.7.3 Right to privacy 
 
The right to privacy refers to the right of the research respondent to determine the 
manner in which personal information will be shared or withheld from another party 
(Grove et al 2013:69). The researcher was granted access by the Provincial 
Department of Health as no contact was made with the patients while carrying out the 
study. Only the researcher had access to the patients’ information prior to coding. 
 
3.7.4 Right to anonymity and confidentiality 
 
Anonymity refers to a situation where the identity of the research respondents and the 
responses provided during data collection will not be linked back to them by any 
individual. Confidentiality refers to the proper management of information provided by 
the research respondents for the purpose of the study such that the information will not 
be shared or disclosed to others without prior authorisation from them (Grove et al 
2013:172). The respondents thus have the right to anonymity in addition to the 
understanding that the data collected will be kept confidential. 
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The researcher took the following steps to ensure that breach of anonymity and 
confidentiality did not occur: 
 
 Collation of the required information from the clinic records was done solely by 
the researcher. 
 Assigning a unique identification code to represent each patient record. This was 
carried out after data cleaning and prior to commencing analysis. 
 Storing the data in a locked cabinet and the soft copies in a password-protected 
and secured database maintained by the researcher. 
 The study findings were reported in a way that the information could not be 
traced to any individual. 
 
3.7.5  Right to fair treatment 
 
This is based on the ethical principle of justice and dictates that everyone should be 
treated fairly (Grove et al 2013:173). In upholding this principle during the study, 
selection of research respondents was based on the requirements for the study and not 
on their vulnerability (Polit & Beck 2012:155). No one was discriminated against on the 
basis of their disease status or social standing. Though there was no direct interaction 
with the research respondents, the researcher demonstrated respect for their different 
backgrounds. The Provincial Department of Health was also afforded the right to 
terminate the study at any stage without any litigation. 
 
3.7.6 Right to protection from discomfort or harm 
 
This is based on the ethical principle of beneficence which indicates that the researcher 
should do well and not harm the respondents (Grove et al 2013:174). Though there was 
no direct invasion of privacy by the researcher while accessing the records of the 
respondents, the benefits of the study outweighs the possible harm that could befall the 
participants. There was no monetary reward to them. However, the findings of the study 
will be shared with the provincial health authorities with recommendations aimed at 
enacting more positive intervention strategies in the area of TB disease control. 
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3.7.7 Scientific integrity of the researcher 
 
The goal of the study is to generate sound scientific knowledge. This is possible through 
honesty in conducting, reporting and publication of studies (Burns & Grove 2005: 187). 
The Department of Health Studies, University of South Africa maintains list of events 
that typifies research misconduct. These include plagiarism, dishonesty, personal 
accountability, and adhering to the University rules and regulations pertaining to 
research. 
The researcher did not display misconduct during the course of the study by carrying 
out the following steps: 
 
 Avoided plagiarism and other forms of dishonesty by ensuring proper referencing 
of ideas, words and findings made by other researchers. 
 Undertook the research in such a manner that the values of the environment and 
the society were not threatened. 
 Observed sound ethical principles during all stages of the study, including when 
the research respondents were selected and when data was extracted from their 
clinic records.   
 Preserved the research data in the prescribed manner and ensured 
confidentiality at all times. 
 Provided an accurate report of the study findings and sound recommendations 
that will impact positively on society. 
 Maintained a fair and open relationship with the Supervisor and the relevant 
authorities of the university. 
 
3.8 DATA COLLECTION 
 
3.8.1 Data sources  
 
The data for the study was sourced from the clinic records of patients who complied 
with the inclusion criteria of the study. Sourcing data from pre-existing medical records 
and documents is advantageous because they enable examination of trends of a 
phenomenon under study over a period of time especially when data is collected 
repeatedly (Manda 2009:63). It also eliminates bias which could be introduced into the 
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study by twisting responses when they are sourced directly from the respondents. 
Recall biases are also reduced. These could occur when respondents are approached 
physically to provide information relating to a study by recalling the events that 
transpired during the period under review.  
 
The researcher did not encounter any uncooperative stance from the participants since 
the data was sourced from the records (Polit & Beck 2012:190). Polit and Beck 
(2012:190) further indicate that collection of original data could be time-consuming and 
expensive. The choice to review records was to minimise cost and time, yield data that 
could not be influenced by the respondents and also allow for comparison 
(Katzenellenbogen & Joubert 2007:108).  
 
The clinic records utilised for the study were kept at the facility. Each patient who 
accessed care at the clinic has a unique identifier that enables better filing and easy 
retrieval by the Administration Clerk employed by the Provincial DOH. The identifiers 
are in the form of alphabets and numbers and are clearly written out on the patients’ 
clinic records. 
 
The identifiers that belong to patients commenced on IPT within the stipulated period 
were initially extracted from the daily clinic attendance register and IPT register. The 
daily attendance register supplied centrally by the Province basically contains the 
identifiers, name of patients, gender, age, date of presentation at the local clinic, 
diagnosis, treatment given and outcome. 
 
With the assistance of the clerk, the identified folders containing the patients’ medical 
records were retrieved from the filing section of the facility. The folders contain more 
detailed information about the patients. Apart from the demographic information, the 
details of management for the patient at each presentation at the clinic are in the 
records. These include the date of presentation, brief history of presenting complaints, 
vital signs, examination findings, diagnosis, and management plans. Hard copies of 
investigation results, TB screening tools and treatment charts are also enclosed in the 
folders. Strict confidentiality was maintained while collecting the data and the names of 
the patients were replaced with unique letters on the data-capture sheet.  
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The strategy of sourcing data from the records utilised by the researcher was therefore 
deemed advantageous.  
 
Having worked closely with the facility, the researcher has a good understanding of the 
various tools and record-keeping procedures used in the facility. However, there were 
challenges retrieving some of the folders due to incorrect filing. They were not deemed 
significant enough to affect the findings of the study. The researcher secured the 
necessary authorisations from the relevant authorities and did not experience difficulty 
accessing the required data. 
 
3.8.2 Data-collection approach and method 
 
The researcher used a structured data-collection method. This involved the use of a 
formal written-out data-collection instrument to collect and record information (Polit & 
Beck 2012:191). After review by a panel of research experts and approval from the 
Higher Degrees Committee of the Department of Health Studies at UNISA, the 
researcher sourced the data for the study from the patients’ clinic records that met the 
inclusion criteria (see section 3.5.1). They were entered onto an electronic spreadsheet 
(data-collection instrument) that was developed by the researcher.  The data-collection 
instrument contained a pre-determined set of questions that were meant to be 
answered in a specified sequence. The use of a structured data-collection method 
ensured that the data were relatively easy to quantify and analyse (Polit & Beck 
2012:191). After recording the data, the researcher thoroughly checked the data for 
completeness before proceeding to analyse them. 
 
3.9 STUDY VALIDITY 
 
Study validity refers to a measure of the accuracy of the research findings. This 
provides the main basis for the decision regarding aspects of the findings that are 
deemed sufficiently valid enough as to provide evidence base for practice (Grove et al 
2013:197). Threats to validity are the various reasons that will make the findings of a 
study possibly wrong (Polit & Beck 2012:236). 
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Types of validity include statistical conclusion validity, internal validity, construct validity 
and external validity (Grove et al 2013:197). The internal and external validity of this 
study will be discussed. 
 
3.9.1 Internal validity 
 
Internal validity refers to the extent to which the outcome of the study represents a true 
reflection of reality rather than due to extraneous variables (Grove et al 2013:199).  
 
The following measures were undertaken by the researcher for the purpose of 
enhancing the internal validity of the study: 
 
 The review of records not including a respondent enhanced internal validity as it 
eliminated possible subject attrition. Attrition in the context of a study refers to the 
fact that some research respondents do not complete the experiment for a 
variety of reasons, such as failure to participate in all phases of the study 
(Christensen 2004:204). In selecting the records for the study, there was no 
interaction with a respondent. All the records that met the inclusion criteria within 
the stipulated period of the study were used. 
 There was no influence on the researcher by the province, fellow health workers 
or the patients as the researcher personally collated the information from the 
various clinic records used for the study. This enhanced the internal validity. 
 
3.9.2 External validity 
 
External validity refers to the extent to which the study findings can be generalised 
beyond the sample used for the study (Grove et al 2013:202). Optimal enhancement of 
external validity implies that the outcome of the study can be generalised across 
variations in people, settings, treatments, outcomes and times (Christensen 2004:217). 
 
The clinic records of adult HIV-positive patients aged 18 and above that met the 
inclusion criteria within the stipulated period were used for the study. Since the patients 
whose clinic information was used for the study were from an identified target 
population and setting, the outcome of the study can be generalised to similar groups of 
people who share the same social characteristics and psychosocial circumstances. The 
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research respondents were deemed to be representative of the population of HIV- 
positive patients who access IPT services from state clinics located in the rural/ semi-
urban areas. 
 
The guidelines used in managing the patients were drawn up by the National 
Department of Health, South Africa and the KwaZulu-Natal Provincial Department of 
Health. This maintains uniform approaches to IPT across all the health facilities. There 
was no identified variability in management protocols in the course of the study at 
Isithebe Clinic. 
 
The researcher did not interact with patients as only their clinic records were used. This 
eliminated the possibility of refusal to participate in the study and possible selection 
bias. This further strengthened the external validity. 
 
3.10 CONCLUSION 
 
This chapter discussed the research design and methodology used in the study. The 
research methods included population, sampling, data collection and instrument, and 
the ethical considerations. The measures taken to ensure internal and external validity 
were also discussed.  
 
Chapter 4 presents the data analysis and interpretation, with reference to the literature 
review.  
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CHAPTER 4 
 
Data analysis and interpretation  
 
 
4.1 INTRODUCTION 
 
This chapter discusses the data analysis and interpretation and the findings. 
 
The research objectives were to describe: 
 
 The demographic characteristics (age and gender) of adult HIV-positive clients 
on antiretroviral therapy who received isoniazid preventive therapy. 
 The incidence of tuberculosis among clients that completed a 6-month course of 
IPT. 
 The defaulter rate for adult clients that were commenced on IPT. 
 
The results of the data analysis extracted from the clinic records of 104 patients who 
met the inclusion criteria (see chapter 3, section 3.5.1) are discussed. 
 
4.2 DATA MANAGEMENT AND ANALYSIS 
 
Data analysis refers to the process of organising, interpreting and communicating 
numerical information (Polit & Beck 2013:379). Descriptive and analytic statistics were 
used to describe and synthesise the data. The researcher engaged the services of a 
Public Health Practitioner/Statistician who analysed the data, using the IBM SPSS 
statistical software program version 21. While descriptive statistics were used to 
describe the demographic characteristics, analytical statistics using the Chi-square test 
measured the associations between gender and age distributions of the respondents 
and those that completed IPT at six and nine months. The 95% level of confidence 
(95% CI) and a probability of p<0.05 were used as the definition of significance while 
comparing the groups. The study findings are discussed in line with the study objectives 
and presented in the form of graphs and tables. 
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In the discussion of the results the following will apply: 
 
N: Capital letter “N” will represent the total number of files audited. 
n:  Small letter “n” will represent the number of files that were included when a 
specific issue was audited, thus excluding the files where that information was 
not available or where only files of one gender were compared with the other 
gender. 
f:  Small letter “f” will represent the frequency. 
%:  The sign % will represent the percentage from either “n” or “N”, where applicable. 
 
4.3 RESEARCH RESULTS 
 
4.3.1 Baseline characteristics of the study population 
 
A total of 104 (N=104) clinic records of HIV-positive adults accessing care at Isithebe 
Clinic that met the inclusion criteria were abstracted for analysis. Prior to commencing 
the analysis, the recorded data were crosschecked to ensure correctness. Of the 
respondents, 63.5% (n=66) were female and 36.5% (n=38) were male (see figure 4.1).  
 
 
Figure 4.1  Gender distribution of research respondents 
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The youngest respondent was 24 and the oldest was 77 years old at the time of 
reviewing the clinic records. The mean age was 40.95 (standard deviation 8.467). For 
ease of analysis, the respondents were grouped into six age groups. The researcher 
used a 10- year interval for age analysis. The age group 38-47 had the highest 
frequency (39.4%; n=41), followed by 28-37 (36.5%; n=38). Only one respondent was 
aged between 58 and 67. Figure 4.2 is a bar chart illustrating the respondents’ ages in 
groups. The highest number of male respondents was in the 28-37 age group while 
most female respondents were between 38 and 47. In the age groups 18-27 and 68-77, 
there were only two male respondents in each group.  
 
 
Figure 4.2   Age distribution of research respondents 
 
The finding of more female respondents is similar to the trend in the HIV epidemic in 
South Africa where the HIV incidence is higher among women compared to their male 
counterparts (Rehle, Hallett, Shisana, Pillay-Van Wyk, Zuma, Carrara & Jooste 2010:4).  
In 2012, the age group with the highest prevalence of HIV among antenatal women was 
found to be 30-34 followed by 35-39 (NDOH 2013b:26). Rehle, Hallett, Shisana, Pillay-
van Wyk, Zuma, Carrara and Jooste (2010:5) found the highest prevalence of men with 
HIV in the 30-34 years age group. This is similar to the finding of this study though the 
researcher did not use the exact age grouping as the NDOH and Rehle et al (2010) 
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4.3.2 Uptake of IPT among research respondents 
 
All the research respondents were screened for TB prior to commencing intake of IPT. 
This was one of the inclusion criteria. In addition to using the screening tool, 12 of the 
respondents had their sputum tested for AFB prior to initiation on ART. The sputum 
testing was because they answered in the affirmative to at least one of the questions in 
the screening tool. It was therefore important to exclude a diagnosis of TB. 
 
Figure 4.3 indicates that 31.7% (n=33) of the respondents completed IPT at six months 
At the end of nine months, 63.5% (n=66) of the respondents completed IPT (see figure 
4.4). This was because some respondents missed collecting their medications for some 
months or the isoniazid used for IPT was out of stock, but they did complete IPT within 
nine months. Treatment default in the context of TB management refers to a situation 
where interruption of treatment was recorded for two months or more (WHO 2013e:6). 
However, according to the IPT guidelines of the NDOH (2010c:5), the six months 
course of IPT can be completed within nine months. Thus defaulting IPT occurs when 
the treatment was not completed within nine months of commencement. The remaining 
38 of 104 (36.5%) respondents were deemed to have defaulted as they did not 
complete IPT within nine months (see figure 4.4).  
 
In a least-cost analysis study of IPT for TB in HIV-seropositive patients, Masobe, Lee 
and Price (1995:77) found an adherence rate of 68.5% in their epidemiological model. 
However, the index study findings revealed that 63.5% had completed the course of 
IPT. The proportion noted in this study is slightly higher when compared to Aisu, 
Raviglione, Van Praag, Eriki, Narain, Barugahare, Tembo, McFarland and Engwau’s 
(1995:267) finding that 62% of their respondents adhered to IPT. Also, in a study of 
adherence to TB preventive therapy among HIV-infected persons in Thailand, 
Ngamvithayapong, Uthaivoravit, Yanai, Akarasewi and Sawanpanyalert (1997:109) 
reported 69.4% adherence to IPT. Golub et al (2009:4) found an IPT adherence rate of 
59%. Compared to the adherence rates of similar studies in various countries, the 
adherence rate of 68.5% was slightly higher. A more recent study in Addis Ababa 
Ethiopia found the level of adherence to IPT to be 89.5% (Berhe, Demissie & Tesfaye 
2014:3). This adherence was self-reported and was defined as those that took more 
than 80% of their medications in the preceding one week prior to the study. 
 77 
 
Figure 4.3   Proportion of respondents completed IPT at 6 months 
 
 
 
Figure 4.4   Proportion of respondents completed IPT at 9 months 
 
Figure 4.5 indicates that of the respondents, 18.4% (n=38) defaulted IPT because the 
drug was out of stock at the clinic; 13.2% (n=38) who defaulted were lost to follow-up, 
while 68.4% (n=38) defaulted solely because IPT was not prescribed for them. The 
exact reason for this was not stated in the clinic records of the affected patients.  Thus, 
out of a total 38 respondents, 86.8% (n=38) defaulted because they did not receive IPT 
from the clinic for some months despite attending the clinic for their ART.  
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Figure 4.5   Reasons for defaulting IPT 
 
According to Goudge, Gilson, Russell, Gumede and Mills (2009:15), to ensure quality of 
care, the needed drugs to prevent TB should always be available to the patient. In this 
study, it was of concern that 33 out of 38 respondents who did not complete their 
treatment defaulted because IPT was not available to them: either not prescribed (26) or 
out of stock (7). This had a negative impact on the quality of care, further compounded 
by the fact that the clinic the respondents attend is within the catchment area of very low 
socio-economic class clients.  
 
The reasons why 5 respondents were lost to follow-up were beyond the scope of this 
study as the reasons were not included in the files of the respondents. However, 
Ngamvithayapong (1997:110) reported outmigration for job search, HIV-status denial, 
side-effects of IPT and ignorance of the duration of treatment as the reasons for 
defaulting IPT. These might or might not be some of the reasons why the respondents 
in this study were lost to follow-up. 
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4.3.3 Gender distribution of respondents that completed IPT at six months  
 
Table 4.1 Gender distribution of respondents that completed IPT at six months 
 
 Female Male Total 
Count 
% within 
gender 
Count 
% within 
gender 
Number % 
Completed 
at 6 months 
No 51 77.3 20 52.6 71 68.3 
Yes 15 22.7 18 47.4 33 31.7 
Total 66 100.0 38 100.0 104 100.0 
 
 
Table 4.1 indicates that the analysis of the respondents’ gender distribution revealed 
that only 22.7% (15 of 66) of the females while 47.4% (18 of 38) of the males completed 
at six months. Of these respondents, 77.3% (51) of the females and 52.6% (20) of the 
males did not complete IPT at six months. 
 
It could be deduced from the cross-tabulation that gender plays a role on whether a 
patient completes IPT at six months (p<0.05) (see table 4.2).  
 
Table 4.2 Chi-square test for gender distribution of respondents that completed 
IPT at six months 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 6.759
a
 1 .009   
N of Valid Cases 104     
a. 0 cells (.0%) have expected count less than 5.  
b. Computed only for a 2x2 table 
 
4.3.4 Gender distribution of respondents that completed IPT at nine months 
 
The number of female respondents who completed IPT within six months increased to 
57.6% (n=15) at nine months. This proportion accounted for 36.5% of all the 
respondents who completed (see table 4.3). 
 
However, 73.7% (n=28) of the male respondents, representing 26.9% of all the 
respondents, completed IPT at the end of nine months. This represents an increase 
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compared to 18 males who completed IPT at the end of six months. Though inferential 
statistics indicate that males are more likely to adhere to the initial six months of IPT, 
there was no statistical significance between female and male respondents who 
completed IPT at nine months (see table 4.4).  
 
Table 4.3    Gender distribution of respondents that completed IPT at nine months  
 
 Female Male Total 
Count 
% within 
gender 
Count 
% within 
gender 
Number % 
Completed 
at 9 
months 
No 28 42.4 10 26.3 38 36.5 
Yes 38 57.6 28 73.7 66 63.5 
 Total 66 100.0 38 100.0 104 100.0 
 
Table 4.4 Chi-square test for gender distribution of respondents that completed 
IPT at nine months 
 
 
Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-sided) 
Pearson Chi-Square 2.699
a
 1 .100   
N of Valid Cases 104     
a. 0 cells (0.0%) have expected count less than 5 
b. Computed only for a 2x2 table 
 
Men were found to be more likely to complete a course of IPT at six months while at 
nine months there was no statistical significance between the male and female 
respondents who completed IPT. The lower social and economic status of women, 
which Krishnan, Dunbar, Minnis, Medlin, Gerdts and Padian (2008:102) noted as one of 
the key drivers of the HIV epidemic, could be responsible for this finding.  Women tend 
to shoulder other domestic responsibilities that keep them away from work. Hence they 
could prefer stretching their treatment for fear of losing their jobs as they can only 
collect their medications by absenting themselves from work.  
 
4.3.5 Age distribution of respondents that completed IPT 
 
The age groups of the respondents who completed IPT at six months were analysed. 
The results indicated that the age group 38-47 recorded the highest number of 
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respondents who completed IPT at six months (see table 4.5). A total of 19 out of 41 
(46.3%) respondents aged 38-47 completed IPT at six months. This proportion was 
higher than the figures recorded for respondents aged 28-37, the next most populated 
age group, while 12 out of 38 (31.6%) aged 28-37 completed IPT at six months. The 
majority of the respondents aged 48-57 did not complete IPT at six months: 18 of 20 
(90%) respondents in this age group did not complete IPT at six months. No patients 
aged 18-27, 58-67 and 68-77 completed IPT at six months.  
 
Table 4.5 Age distribution of respondents that completed IPT at six months 
 
Age in group 
Completed IPT at six months (Yes/No) 
Total 
Yes 
% within age 
group 
No 
% within age 
group 
18-27 0 0.0 2 100.0 2 
28-37 12 31.6 26 68.4 38 
38-47 19 46.3 22 53.7 41 
48-57 2 10.0 18 90.0 20 
58-67 0 0.0 1 100.0 1 
68-77 0 0.0 2 100.0 2 
 
 
The inferential statistics illustrated in table 4.6 indicate that age groups play a role in 
determining completion of IPT at six months (p0.057).  
 
Table 4.6 Chi-square test for age distribution of respondents that completed IPT 
at six months 
 
 Value df Asymp. Sig. (2-sided) 
Pearson’s Chi-square 10.725
a
 5 .057 
N of Valid cases 104   
a. 6 cells (50.0%) have expected count less than 5.  
 
At the end of nine months on IPT, 80.5% (33 of 41) of the respondents aged 38-47 
completed IPT. Table 4.7 indicates that this was the highest proportion for any age 
group in terms of completion of IPT at nine months as the 33 patients represented 
31.7% of all the respondents. At the same time, 65.8% (25 of 38) of the respondents 
aged 28-37 completed IPT at the end of nine months of treatment with isoniazid. 
Though the numbers are too few for optimal comparison, it was noted that no patients 
aged 18-27 and 58-67 completed IPT at nine months. Using the Chi-square test, it was 
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statistically deduced that age group plays a role in completing IPT at nine months 
(p0.001) (see table 4.8). 
 
Table 4.7 Age distribution of respondents that completed IPT at nine months  
 
Age in group 
Completed IPT at nine months (Yes/No) 
Total 
Yes 
% within age 
group 
No 
% within age 
group 
18-27 0 0.0 2 100.0 2 
28-37 25 65.8 13 34.2 38 
38-47 33 80.5 8 19.5 41 
48-57 6 30.0 14 70.0 20 
58-67 0 0.0 1 100.0 1 
68-77 2 100.0 0 0.0 2 
 
Table 4.8 Chi-square test for age distribution of respondents that completed 
IPT at nine months 
 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-square 21.234
a
 5 .001 
N of Valid cases 104   
 
4.3.6 Incidence of TB disease among research respondents 
 
Information extracted from the clinical records indicated that 1% (1 of 104) of the 
research respondents (a male) was diagnosed with active TB disease (see figure 4.6). 
He was aged 48 years and was commenced on IPT on 01 November 2011. He was 
screened with the approved TB screening tool and answered in the affirmative when 
asked about cough and weight loss. Sputum AFB test was done afterwards. The result 
was negative prompting commencement of IPT. Sputum TB culture was not done and 
GeneXpert test was not available at the facility at that time. He was initially managed 
with a five-day course of oral antibiotics. 
 
The respondent defaulted IPT after four months. There was no indication in his record 
that isoniazid was prescribed for him after the initial four months. He continued clinic 
visits for his ART, however, and was diagnosed with TB disease on 11/01/2013 using 
the sputum AFB testing method. At the time his clinic record was accessed for data 
gathering in April 2013, he was on the maintenance phase of anti-TB treatment (see 
figure 2.2). His last recorded CD4 count (reported on 04/12/2014) was 201 cells/mm³ 
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while his viral load result (reported 05/12/2012) was lower than detectable. Thus he was 
virally suppressed and adherent to his ART. Though the study population was relatively 
small when compared to the disease burden of the district, the result is similar to Golub 
et al’s (2009:633) finding that men accessing IPT/ART care were more likely to develop 
TB. This could be related to the general health-seeking behaviour of men. Neglecting 
symptoms until the disease state reaches an advanced stage was found to be the 
typical health-seeking pattern of men (Johansson, Long, Diwan & Winkvist 2000:46). 
 
It is evident from research studies that IPT for six months to patients, successfully 
prevented TB disease. An incidence rate of 0.80 per 100 person-years (Golub et al 
2007:15) and 2.3 per 100 person-years (Rangaka et al 2014:3) were reported.  
 
None of the 66 respondents who completed IPT at the end of nine months was 
diagnosed with TB disease as at the time the study data was gathered.  
 
 
Figure 4.6   Proportion of research respondents diagnosed with TB disease 
 
4.4 CONCLUSION 
 
The study revealed a preponderance of female research respondents over their male 
counterparts. The majority of the respondents were aged 38-47 followed by age group 
28-37. Less than half of the research respondents completed IPT at six months. This 
 84 
proportion increased to 66 out of 104 (63.5%) respondents at the end of nine months 
with 38 (36.5%) of the respondents defaulting IPT. 
 
Gender and age group were found to have played a statistically significant role on the 
completion of IPT at six months. Age group also played a role in completing IPT at nine 
months. Only one male respondent who defaulted on IPT was diagnosed with active TB 
disease within the period the study covered. None of the respondents who completed 
IPT after 9 months was diagnosed with TB disease within the study period. 
 
Chapter 5 presents findings, briefly describes the limitations, contribution and 
significance of the study, and makes recommendations for practice and further 
research.  
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CHAPTER 5 
 
Contributions, limitations, conclusions and recommendations  
 
 
5.1 INTRODUCTION 
 
Isoniazid preventive therapy (IPT) is one of the interventions recommended by the 
WHO for preventing progression of latent TB infection to active TB disease. No known 
scientific study has been conducted in iLembe district to ascertain uptake of IPT and the 
efficacy of this intervention. 
 
The purpose of this study of limited scope was to describe the incidence of TB among 
HIV-positive clients who received IPT in a specific PHC centre in iLembe district in order 
to recommend positive intervention strategies aimed at improving uptake of IPT. The 
study also explored the defaulter rate among respondents who were commenced on 
IPT, in order to recommend ways of optimising adherence to IPT. 
 
Both descriptive and analytical statistics were used in analysing the audited data from 
the clinic records of the study population.  
 
5.2 CONTRIBUTIONS OF THE STUDY 
 
The finding that most of the research respondents who defaulted IPT did so due to not 
dispensing revealed a major shortcoming in the healthcare system. The researcher will 
share the study findings with the facility, the district and the Provincial Department of 
Health through the provincial Health Research Committee. This will enable the province 
and the district to act in terms of more efficient drug supply management and implement 
the recommendations of the researcher. 
 
The study also strengthened the findings of similar local and international studies that 
IPT is advantageous. Not one respondent who completed IPT developed active TB 
disease within the period the study covered. This message should be passed on to the 
entire public at every appropriate forum, such as continuous professional development 
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sessions, poster presentations and oral presentations at conferences. The researcher 
will also submit a manuscript for possible publication in the accredited peer reviewed 
journal, South African Medical Journal, to disseminate these results. 
 
5.3 LIMITATIONS OF THE STUDY 
 
Since this study is a dissertation of limited scope, the researcher only used data from 
one district. This study is only one of the modules in the Master of Public Health degree 
and the limitations should be seen in this context.  
 
The retrospective design of the study that involved the analysis of the data from clinical 
records of research respondents was a limiting factor. The information in the clinical 
records was primarily for the management of the patient. As a result, the researcher 
could not extract demographical information like socio-economic characteristics, 
adverse drug reactions, psychosocial issues, pill burden and other reasons that may 
have influenced IPT intake. The researcher was thus limited in finding the reason for not 
prescribing IPT to some patients as the study was restricted to reviewing available clinic 
records which did not provide such information.  
 
The 104 clinic records used for the study are far below the number of adult patients who 
tested positive for HIV in the clinic and which the researcher thought could have been 
included. The key finding was that not all of them were screened for TB at each visit and 
therefore needed to be excluded, thereby contributing to the small sample. It is possible 
that more cases of TB would have been detected by the researcher if the study 
population was increased and better sensitive and specific TB testing methods utilised 
for all the respondents during the period of the study as opposed to the use of the TB 
screening tool. 
 
5.4 CONCLUSIONS 
 
5.4.1 Gender and adherence 
 
The data revealed that after a six-month period, which is the preferred time for 
completing the IPT regimen, the percentage of male adherence (47.4%) was much 
higher than that of females (22.7%). After nine months, which can still be seen as 
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adherence according to the NDOH (2010c:5), 73.7% of males completed, but only 
57.6% of the females did. 
 
Recommendation  
 
The Department of Health should consider and explore other ways of getting chronic 
medications, like IPT across to the deserving patients. Community health care workers 
should be trained to be the responsible for dispensing IPT to patients at their homes, 
after official hours or during weekends. Women, who tend to put other domestic 
responsibilities as well as fear of losing their jobs if they are absent from work, before 
their own health, will then be able to adhere to the IPT treatment within the six-month 
period as required. This might contribute to the improvement of adherence to IPT by 
women. The adherence of males can be further improved if they also receive their 
medication at home and at work where applicable. Companies that engaged the 
services of Occupational Nurse could capacitate them to dispense IPT to their 
deserving members of staff. 
 
5.4.2 Default due to unavailability of IPT 
 
Of the respondents, 38 of 104 (36.5%) defaulted intake of IPT, with only 5 due to not 
attending the clinic, thus only 5 participants were responsible for the default. For all the 
others who defaulted therefore it seemed as if poor quality of care was the main factor 
associated with the default. Either IPT was not prescribed for some reason, or was out 
of stock. The current recording system did not allow the researcher to access whether 
the IPT was out of stock or was simply not prescribed. It is therefore possible that some 
healthcare workers have not fully accepted the advantages of IPT in terms of reducing 
the incidence of active TB, or still harbour reservations about prescribing IPT due to the 
perceived side effects or development of resistance to INH used for IPT (Rangaka et al, 
2014:7; Golub et al, 2007:1442). It also may be that IPT was not available to be 
prescribed, thus out of stock at the clinic. 
 
Recommendation 
 
A system that will ensure timely procurement of medication should be adopted to 
ensure the provision of quality healthcare service to patients. Each healthcare facility 
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(clinic or department) should appoint a healthcare worker or workers to take 
responsibility for procurement of medication. Alternatively, this task should be delegated 
to a specific healthcare worker who will be held responsible and accountable if the 
medication is not available for prescription. This responsibility lies with the Pharmacy 
Assistant in facilities where they are available. The availability of IPT for prescription, as 
all other medications, should be checked on a chart on a daily basis. This responsibility 
should be incorporated in the performance appraisal of the personnel and the 
consequences for neglect should be stipulated. In this way, quality healthcare can be 
improved and the adherence rate will improve. 
 
Healthcare personnel, especially the doctors who need to prescribe the drug, and the 
pharmacy assistants/nurses who are responsible for ensuring that the drugs are 
ordered, need to attend continuous professional development sessions where IPT is 
addressed. Attending these sessions should also form part of the performance appraisal 
of these professionals.   
 
Other measures aimed at further reducing the defaulter rate for IPT should be 
implemented. These include but are not limited to ongoing adherence counselling, 
regular screening for side effects of IPT, and improving accessibility to IPT.  
 
5.4.3 Incidence of TB among respondents who completed IPT 
 
None of the 66 respondents who completed the course of IPT at the end of nine months 
was diagnosed with TB disease at the time the study data was gathered.  Only one 
male respondent was diagnosed with TB after he defaulted IPT at four months. The 
exact reason for defaulting was not stated in the clinic records.  
 
It is evident from the study results that the use of IPT proved to be a successful 
intervention in preventing HIV-positive patients from developing TB disease. It remains 
of serious concern that the uptake of IPT was still low despite the advantages of IPT 
use and the NDOH (2013:14) and WHO (2011a:6; 2011b:1) recommendations.   
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Recommendation 
 
The most current national treatment guidelines in South Africa (DOH 2014:85) 
recommend the use of tuberculin skin test (TST) prior to commencing IPT. This practice 
of carrying out TST prior to commencing IPT should be standardised to ensure that the 
appropriate duration of IPT is adopted. However, if research evidence is to be 
implemented and evidence-based practice to be delivered to healthcare consumers, the 
healthcare workers need to take responsibility for the quality of the care that they 
deliver. 
 
Performance appraisal should include aspects such as timely ordering of medication, 
accountability for negligence to order medication, attending workshops and continuous 
professional development sessions. Healthcare professionals who do not comply with 
their agreed upon performance appraisal should be held accountable for poor quality of 
healthcare with the necessary action taken against them.   
 
5.5 GENERAL RECOMMENDATIONS  
 
The researcher recommends strengthening of the data management system at the 
clinics to ensure enhanced capturing of dispensed IPT. This includes designing less 
cumbersome registers; enhancing the data-capturing abilities of the healthcare workers 
and data capturers; yearly didactic training sessions at the district and mentorship at the 
institutional level by experienced district information management team who have rich 
and updated knowledge of the district information system.  
 
A formal mentorship agreement between a senior and a junior colleague to ensure that 
junior personnel are mentored and supervised should be implemented. The exact 
reason for not prescribing any medication should be clearly written in the progress 
notes. 
  
5.6 RECOMMENDATIONS FOR FURTHER RESEARCH  
 
Due to the limited scope of the study, only one PHC clinic was included in the study. A 
national study can be conducted to enable generalisation of the findings so that 
recommendations can be implemented at national level.   
 
90 
The researcher recommends inclusion of demographic data like monthly income, 
educational status and the type of accommodation both in the manual and electronic 
IPT registers. This will enable further studies on the possible impact of demographic 
characteristics on the uptake of IPT as the utilisation of IPT has already proved 
advantageous.  
  
5.7 CONCLUDING REMARKS 
 
Gender differences still exist in relation to health-seeking behaviour. The finding of men 
being more likely to complete a course of IPT within six months collaborates this. It 
remains a serious concern that inadequacies or incompetence of healthcare providers 
were the main reasons for defaulting Isoniazid Preventive Therapy as isoniazid was not 
dispensed to the patients. None of the patients who completed the course of IPT 
contracted active TB disease during the duration of the study. Intervention strategies to 
improve uptake of IPT must be advocated. 
 
His experience as a medical doctor and the insight and understanding he gained from 
the study have enriched the researcher. The findings should benefit policy makers, 
healthcare professionals, and particularly the patients in need.   
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